Download CV Output - Baker Institute

CURRICULUM VITAE
John Mendelsohn, M.D.
PRESENT TITLE AND AFFILIATION
Primary Appointment
Past President, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Institute for Personalized Cancer Therapy, Division of Cancer Medicine, The University
of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University
of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Member, Graduate Faculty, Graduate School of Biomedical Sciences, Houston, TX
L.E. and Virginia Simmons Senior Fellow in Health and Technology Policy, James A. Baker, III
Institute for Public Policy
CITIZENSHIP
United States
OFFICE ADDRESS
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 0491
Houston, TX 77030
Room Number: FC12.2010
Phone: 713-792-6670
Fax: 713-792-6671
Email: [email protected]
EDUCATION
Degree-Granting Education
Harvard University, Cambridge, MA, BA, Magna Cum Laude, 1958, Biochemical Science
University of Glasgow, Glasgow, United Kingdom, Scotland, Fulbright Scholar, 1959, Research in
Molecular Biology
Harvard Medical School, Boston, MA, MD, Cum Laude, 1963, Medicine
Postgraduate Training
Clinical Internship, Medicine, Peter Bent Brigham Hospital, Boston, MA, 1963-1964
Assistant Resident, Medicine, Peter Bent Brigham Hospital, Boston, MA, 1964-1965
Research Associate, National Institutes of Health, Bethesda, MD, 1965-1967
Senior Resident, Medicine, Peter Bent Brigham Hospital, Boston, MA, 1967-1968
Assistant, Medicine, Harvard Medical School, Boston, MA, 1967-1968
Fellow, Hematology, Washington University, St. Louis, MO, 1968-1970
CREDENTIALS
John Mendelsohn, M.D.
Board Certification
American Board of Internal Medicine, 1969
American Board of Internal Medicine, Hematology, 1973
American Board of Internal Medicine, Medical Oncology, 1979
Licensures
Active
CA, #CA 19232, 10/1970
TX, #K-4619, 2/1998
Inactive
MO, #R-3281, 5/1968-1999
NY, #161416-1, 2/1985-7/2007
EXPERIENCE/SERVICE
Academic Appointments
Instructor, Medicine, Washington University, St. Louis, MO, 1968-1970
Assistant Professor, University of California, San Diego, CA, 1970-1974
Associate Professor, University of California, San Diego, San Diego, CA, 1974-1979
Professor, University of California, San Diego, CA, 1979-1985
Attending Physician, Memorial Hospital, New York, NY, 1985-1996
Professor, Medicine, Cornell University Medical College, New York, NY, 1985-1996
Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University
of Texas MD Anderson Cancer Center, Houston, TX, 1996-present
Member, Graduate Faculty, Graduate School of Biomedical Sciences, Houston, TX, 1998-present
Administrative Appointments/Responsibilities
Co-Head, Hematology/Oncology, University of California, San Diego, San Diego, CA, 1976-1985
Founding Director of Cancer Center, University of California, San Diego, San Diego, CA, 19761986
Co-Chairman, Sloan-Kettering Institute for Cancer Research, New York, NY, 1985-1990
Vice-Chairman, Medicine, Cornell University Medical College, New York, NY, 1985-1996
Chairman, Memorial Hospital, New York, NY, 1985-1996
President, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-2011
Director, Institute for Personalized Cancer Therapy, Division of Cancer Medicine, The University
of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-present
Past President, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2012present
Other Appointments/Responsibilities
Consultant Lecturer, Naval Regional Medical Center, San Diego, CA, 1974-1985
Consultant Lecturer, Camp Pendleton, San Diego, CA, 1974-1985
Member, Cancer Advisory Council of the State of California, San Diego, CA, 1979-1985
Member, Advisory Committee, National Flow Cytometry Resources at Los Alamos National
Laboratory, Los Alamos, NM, 1982-1985
Member, Oncology Advisory Board, Schering Corporation, Kenilworth, NJ, 1985-1986
Member, Memorial Sloan-Kettering Cancer Center, New York, NY, 1985-1996
Member, Sloan-Kettering Institute for Cancer Research, New York, NY, 1985-1996
Page 2 of 38
John Mendelsohn, M.D.
Attending Physician, New York Hospital, New York, NY, 1985-1996
Visiting Physician, Rockefeller University Hosptial, New York, NY, 1985-1996
Member, Biological Response Modifiers Program Decision Network Committee, Unknown,
Unknown, 1986-1987
Member, Division of Cancer Treatment Board of Scientific Counselors, Unknown, Unknown,
1986-1990
Member, Oncology Advisory Board, Hoffmann-LaRoche, Unknown, CA, 1987-1989
Member, Scientific Advisory Board, Lineberger Cancer Center, University of North Carolina,
Chapel Hill, NC, 1987-1989
Member, Oncology Advisory Board, Genentech, Inc., South San Francisco, CA, 1987-present
Member, Scientific Advisory Board, Institute for Molecular Pathology, Vienna, Italy, 1988-1991
Member, External Review Committee, Stanford University Medical Center, Division of Oncology,
Unknown, CA, 1988-1991
Member, Board of Scientific Counselors, National Cancer Institute, Division of Cancer Treatment,
Bethesda, MD, 1989-1992
Member, Scientific Advisory Committee, Immunex, Thousand Oaks, CA, 1990-1992
Member, Advisory Committee, University of Wisconsin Comprehensive Cancer Center, Madison,
WI, 1990-1993
Member, Scientific Advisory Committee, Bristol Myers Squibb, Park Avenue, NY, 1990-2002
Member, Scientific Advisory Board, ImClone Systems, Inc., New York, NY, 1992-2002
Member, Task Force for an NIH Strategic Plan, Bethesda, MD, 1992
Member, Scientific Advisory Board, NCI-EORTC Symposia on New Drugs in Cancer Therapy,
Bethesda, MD, 1992
Member, Advisory Board, International Congress on Anticancer Chemotherapy, Unknown, 1993
Chairman, John Hopkins Oncology Center External Advisory Board, Baltimore, MD, 1993
Member, Advisory Group, Selective Genetics, Inc. (formerly Prizm, Inc.), San Diego, CA, 1993
Member, Abbott Biotech, Inc., unknown, 1994-1995
Member, Scientific Advisory Committee, Imperial Cancer Research Fund, Unknown, United
Kingdom, 1994
Member, General Motors Cancer Research Foundation Awards Assembly, Unknown, 1995-1997
Member, Board of Directors, Richard Lounsbery Foundation, Washington, DC, 1995-2000
Member, Scientific Advisory Board, Merck Institute, Rahway, NJ, 1995-2000
Member, Scientific Advisory Board, Progenics Pharmaceuticals, Inc., Tarrytown, NY, 1995
Scientific Advisor for Cancer Research, Pfizer, New York, NY, 1995
Chairman, External Advisory Committee, Washington University Cancer Center, St. Louis, MO,
1996-1998
Member, DOD Prostate Cancer Consortium Advisory Board, Unknown, 1996-present
Member, Advisory Committee, The Rotary Lombardi Award, Unknown, 1996
Member, Houston Grand Opera Board of Trustees, Houston, TX, 1996
Member, Institute of Medicine, National Academy of Sciences, Washington, DC, 1996
Member, National Dialogue on Cancer, Unknown, 1996
Member, Board of Governors, The Houston Forum, Houston, TX, 1997-1999
Page 3 of 38
John Mendelsohn, M.D.
Member, Board of Scientific Counselors for Intramural Research Programs, National Cancer
Institute, Bethesda, MD, 1997-2001
Member, Board of Directors, Greater Houston Partnership, Houston, TX, 1997-2003
Member, Executive Committee, Greater Houston Partnership, Houston, TX, 1997-present
Honorary Trustee, Board of Trustees, Gulf Coast Regional Blood Center, Houston, TX, 1997
Member, Board of Directors, ImClone Systems Incorporated, New York, NY, 1998-2003
Member, Board of Directors, Houston Technology Center, Houston, TX, 1998-9/2009
Member, Executive Committee, The Houston Forum, Houston, TX, 1998
Member, Science Division of the Royal Netherlands Academy of Arts and Sciences, Amsterdam,
Netherlands, 1998
Member, U.S. House of Representatives Taskforce to Reevaluate Medicare Reimbursements for
Training Doctors at Teaching Hospitals (Headed by Congressman Nick Lampson), Austin, TX,
1999-2000
Member, National Cancer Policy Board, Washington, DC, 1999-2002
Member, Board of Directors, Enron Corporation, Houston, TX, 1999-2002
Member, Scientific Advisory Board, Thyreos Corporation, Newark, NJ, 1999-2003
Inaugural Member, Damon Runyon Cancer Research Foundation Clinical Investigator Award
(CIA) Committee, New York, NY, 1999-2008
Member, External Advisory Committee, University of California San Diego Cancer Center, San
Diego, CA, 1999
Member, Business Issues Advisory Committee, Greater Houston Partnership, Houston, TX, 20002002
Member, Board of Directors, Center for Houston's Future, Houston, TX, 2000-2007
Member, Health Services Steering Committee, Greater Houston Partnership, Houston, TX, 2000present
Member, Team on Cancer Research, National Dialogue on Cancer, Washington, DC, 2001
Member, Advisory Board, Harvard Medical School, Boston, MA, 2001
Member, Board of Directors and Vice Chairman, BioHouston, Houston, TX, 2001
Member, Institute of Medicine and Division of Earth and Life Sciences' Committee on Large-Scale
Science and Cancer Research, Washington, DC, 2002-2003
Member, Governor's Council on Science and Biotechnology Development, Austin, TX, 2002
Member, Scientific Advisory Committee Biotherapy, Biotherapy Development Association, Cancer
Research UK, Unknown, United Kingdom, 2003
Member, Singapore's Biomedical Sciences International Advisory Council, Unknown, Singapore,
2003
Member, Scientific Advisory Board, Centro Nacional de Investigaciones Oncologicas (CNIO),
Madrid, Spain, 2003
Member, Strategic Planning Committee, Greater Houston Partnership, Houston, TX, 2005present
President, Institut Gustave-Roussy Scientific Council, Paris, France, 2005
Vice Chair, Agency for Science, Technology and Research Advisory Committee, Unknown, 2005
Honorary Committee Member, American Hospital of Paris 100th Anniversary Gala, Paris, France,
2006-2007
Page 4 of 38
John Mendelsohn, M.D.
Member, Board of Directors, Texas Institute for Genomic Medicine, Houston, TX, 2006
Member, Advisory Committee, Holocaust Museum Houston's 2007 Exhibit, Houston, TX, 2006
Chair, Cancer Center Director's Working Group, National Cancer Institute, Bethesda, MD, 2006
Member, Scientific Advisory Board, Targeted Molecular Diagnostics, LLC, Westmont, IL, 20072011
Member, Finance Committee, The Academy of Medicine, Engineering and Science of Texas,
Austin, TX, 2007
Chair, Planning Committee for Cooperative Groups (subcommittee of the forum), N/A, 2007
Member, Advisory Council of the Board of Directors, Center for Houston's Future, Houston, TX,
2007
Member, National Cancer Policy Forum, Institute of Medicine, Bethesda, MD, 2008-2011
Member, International Advisory Board of King Hussein Institute for Biotechnology and Cancer,
N/A, 2008
Member, Board of Advisors of the Bilateral US Arab Chamber of Commerce, Houston, TX, 2008
Member, Scientific Advisory Board, American-Italian Cancer Foundation, New York, NY, 2008
Member, Scientific Advisory Board, National Center for Tumor-Disease, Germany, Germany,
2008
Member, Planning Committee, Institute of Medicine of The National Academies, Washington, DC,
2011-2012
Endowed Positions
Winthrop Rockefeller Chair in Medical Oncology, Memorial Sloan-Kettering Cancer Center, New
York, NY, 1985-1996
Consultantships
North Shore University Hospital, Manhasset, NY, Consulting Staff, 1985-1996
Texas Medical Association, Austin, Texas, Council on Medical Education, 1996
Military or Other Governmental Service
U.S. Public Health Service, Unknown, 7/1965-6/1967
Institutional Committee Activities
External Advisory Committee for Research, M. D. Anderson Cancer Center, Member, 1995-1996
Institutional Compliance, Chair, 1996-present
Audit, Member, 1996-present
Compensation Policy Committee, Chair, 1996-present
Facilities Steering Committee, Chair, 1996-present
Management Committee, Chair, 1996-present
President's Advisory Board, Chair, 1996-present
Research Council, Ex-Officio, 1996-present
University Cancer Foundation Advisory Board, Chair, 1996-present
Information Systems Steering Committee, Member, 1996
Clinical Council, Ex-Officio, 1996
Institutional Review Board (Surveillance Committee), Ex-Officio, 1996
Leadership Forum, Member, 1996
Committee on Faculty Awards, Member, 2012-present
Page 5 of 38
John Mendelsohn, M.D.
HONORS AND AWARDS
Phi Beta Kappa, Harvard College, 1958
United States Fulbright Scholar in Biochemistry, University of Glasgow, Scotland, 1958-1959
Alpha Omega Alpha, Harvard Medical School, 1962
First Prize, Boylston Society Essay Contest, Harvard Medical School, 1963
Research Career Development Award, National Institutes of Health, 1973-1978
Professor of Clinical Oncology, American Cancer Society, 1982-1985
"Headliner of the Year" in Medicine, Press Association, 1985
Merit Award, National Cancer Institute Grant, 1990-1997
Bristol-Myers Squibb Cancer Research Award, 1997
Gold Medal of Paris, 1997
Jill Rose Award for Outstanding Breast Cancer Research, Breast Cancer Research Foundation, 1997
Phi Beta Kappa Outstanding Alumnus Award, Phi Beta Kappa Alumni of Greater Houston, 1997
Raymond Bourgine Award for Excellence in Cancer Research, 1997
4th Joseph H. Burchenal American Association for Cancer Research Clinical Research Award,
American Association for Cancer Research, 1999
Elected Member, Royal Netherlands Academy of Arts and Sciences, 1999
David A. Karnofsky Memorial Award, American Society of Clinical Oncology, 2002
Simon M. Shubitz Award, University of Chicago Cancer Center Research Foundation, 2002
27th Bristol-Myers Squibb Freedom to Discover Award for Distinguished Achievement in Cancer
Research, Bristol-Myers Squibb, 2004
Fulbright Lifetime Achievement Medal, 2005
Honorary Doctorate Degree, Naples University, Italy, 2005
Future Time Dimension - in the Field of Cancer Therapy, Dan David Prize and Dan David Foundation,
2006
Honorary Doctorate Degree, Yonsei University, Seoul Korea, 2006
Honorary Doctorate Degree, China Medical University, Taichung, Taiwan, 2006
Loving Hearts and Caring Hands Award, The University of Texas M. D. Anderson Cancer Center,
2006
AICF Prize for Scientific Excellence in Medicine (jointly with Dr. Jose Baselga), American-Italian
Cancer Foundation, 2007
The Norman Vincent and Ruth Stafford Peale Humanitarian Award. Jointly awarded with his wife.,
Guideposts, 2007
Dorothy P. Landon − AACR Prize for Translational Cancer Research, American Association for
Cancer Research, 2008
Lifetime Achievement Award, 10th International Workshop on Molecular Targeted Therapy of Cancer,
2009
Lila Gruber Memorial Cancer Research Award, American Academy of Dermatology, 2009
Ernest W. Bertner Memorial Award, The Unversity of Texas M.D. Anderson Cancer Center, 2010
Heath Memorial Award, The Unversity of Texas M.D. Anderson Cancer Center, 2011
Medal of Honor, American Cancer Society, 2011
Page 6 of 38
John Mendelsohn, M.D.
Sixth Annual American Association for Cancer Research Margaret Foti Award for Leadership and
Extraordinary Achievements in Cancer Research, American Association for Cancer Research, 2012
RESEARCH
Grants and Contracts
Funded
Co-Investigator, 20%, Cancer Center Support Grant, P30-CA16672-30, NIH/NCI, PI - Ronald
DePinho, 9/14/1998-6/30/2013, $51,462,470
Pending
Principal Investigator, 20%, Comprehensive Integration of Genomic Information in Managing
Women's Cancers, National Human Genome Research Institute, 3/1/2013-2/28/2017,
$5,993,249 ($1,483,114/year)
Other
N/A
Completed
Co-Principal Investigator, 1%, The Breast Cancer Research Foundation Grant, The Breast
Cancer Research Foundation, PI - Zhen Fan, 10/1/2007-9/30/2008, $208,334
Not Funded
N/A
Protocols
Funded
N/A
Unfunded
N/A
Patents and Technology Licenses
Patents
University of California at San Diego, Mendelsohn, J. Kawamoto, T, Sato, G. & Sato, J..
Erbitux, United States, 4,943,533, 7/24/1990, Issued
Technology Licenses
N/A
Grant Reviewer/Service on Study Sections
Cancer Therapeutics Program Study Section, NIH, Chair, 1982-1985
PUBLICATIONS
Peer-Reviewed Original Research Articles
1. Mendelsohn J, Tissieres A. Variations in the amount of ribonucleo-protein particles in
Escherichia coli. Biochem Biophys Acta 35:248-250, 1959.
2. Mendelsohn J, Moore DE, Salzman NP. Separation of isolated Chinese hamster metaphase
chromosomes into three size-groups. J Mol Biol 32(1):101-12, 2/1968.
3. Dawson DM, Alper CA, Seidman J, Mendelsohn J. Measurement of serum enzyme turnover
rates. Annals of Internal Medicine 70(4):799-805, 4/1969.
4. Mendelsohn J, Skinner A, Kornfeld S. The rapid induction by phytohemagglutinin of
increased alpha-aminoisobutyric acid uptake by lymphocytes. J Clin Invest 50(4):818-26,
4/1971.
5. Rosenfeld MG, Abrass JB, Mendelsohn J, Ross BA, Boone RF, Garren LD. Control of
transcription of RNA rich in polyadenylic acid in human lymphocytes. Proceedings of the
National Academy of Sciences of the United States of America 69(8):2306-11, 8/1972.
6. Wong-Staal F, Mendelsohn J, Goulian M. Ribonucleotides in closed circular mitochondrial
DNA from HeLa cells. Biochemical and Biophysical Research Communications 53(1):140-8,
7/1973.
Page 7 of 38
John Mendelsohn, M.D.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Mendelsohn J, Multer MM, Boone RF. Enhanced effects of prostaglandin E1 and dibutyryl
cyclic AMP upon human lymphocytes in the presence of cortisol. J Clin Invest 52(9):2129-37,
9/1973.
Rosenfeld MG, Abrass IB, Mendelsohn J, Miller HI, Holland J. Poly(A): possible role in
translation of poly(A)-rich RNA. Proc Soc Exp Biol Med 144(1):215-9, 10/1973.
Fox RM, Mendelsohn J, Barbosa E, Goulian M. RNA in nascent DNA from cultured human
lymphocytes. Nat New Biol 245(147):234-7, 10/1973.
Mendelsohn J, Castagnola JM, Goulian M. On the mechanism for formation of RNA . DNA
complexes from lymphocytes. Biochimica et Biophysica Acta 407(3):283-91, 10/1975.
Mendelsohn J, Fox RM, Goulian M, Barbosa E. Nascent DNA from phytohemagglutininstimulated human lymphocytes. Immunological Communications 4(4):373-85, 1975.
Snyder FF, Mendelsohn J, Seegmiller JE. Adenosine metabolism in phytohemagglutininstimulated human lymphocytes. J Clin Invest 58(3):654-66, 9/1976.
Synder FF, Mendelsohn J, Seegmiller JE. Adenosine Metabolism During
Phytohemagglutinin-Induced Transformation of Human Lymphocytes. Journal of Clinical
Chemistry and Clinical Biochemistry 14(6):322-322, 1976.
Bernheim JL, Dorian R, Djobadze M, Mendelsohn J. Lymphocyte Pha and Ppd Stimulation
as an Invitro Model for Recruitment - Proliferation Kinetics of System. Cancer Treatment
Reports 60(12):1986-1987, 1976.
Bernheim JL, Mendelsohn J, Kelley MF, Dorian R. Kinetics of cell death and disintegration in
human lymphocyte cultures. Proceedings of the National Academy of Sciences of the United
States of America 74(6):2536-40, 6/1977.
Linthicum DS, Elson E, Mendelsohn J, Sell S. Endocytosis and exocytosis of
phytohemagglutinin (PHA) cell surface receptors of human lymphocytes during blast
transformation. Experimental Cell Research 110(2):237-50, 12/1977.
Snyder FF, Mendelsohn J, Seegmiller JE. Adenosine and guanosine metabolism during
phytohemagglutinin induced transformation of human lymphocytes. Advances in
Experimental Medicine and Biology 76A:441-7, 1977.
Mendelsohn J, Multer MM, Bernheim JL. Inhibition of human lymphocyte stimulation by
steroid hormones: cytokinetic mechanisms. Clinical and Experimental Immunology 27(1):12734, 1977.
Vries JD, Caviles AP, Brambilla E, Mendelsohn J. Role of Monocytes (M) in Response of
Human Lymphocytes (L) to Mitogens. Blood 50(5):168-168, 1977.
Bernheim JL, Dorian RE, Mendelsohn J. DNA synthesis and proliferation of human
lymphocytes in vitro. I. Cell kinetics of response to phytohemagglutinin. J Immunol
120(3):955-62, 3/1978.
Bernheim JL, Mendelsohn J. DNA synthesis and proliferation of human lymphocytes in vitro.
II. Characterization of the DNA newly synthesized after phytohemagglutinin stimulation. J
Immunol 120(3):963-70, 3/1978.
Shiftan TA, Caviles AP, Jr, Mendelsohn J. Spontaneous lymphocyte proliferation and
depressed cellular immunity in Hodgkin's disease. Clinical and Experimental Immunology
32(1):144-52, 4/1978.
Taetle R, Mendelsohn J, Green MR. Hypercalcemia and tamoxifen readministered. Annals
of Internal Medicine 89(2):287, 8/1978.
Dorian R, Bernheim JL, Mendelsohn J. Quantification of entry into and exit from the cell
cycle in human lymphocyte cultures. Cell and Tissue Kinetics 11(1):33-44, 1978.
Wohlers R, Mendelsohn J, Kopp RE, Pernick BJ. Screening of Cervical Cytological Samples
Using Coherent Optical Processing .2. Applied Optics 17(1):35-42, 1978.
Shiftan TA, Mendelsohn J. The circulating "atypical" lymphocyte. Human Pathology 9(1):5161, 1978.
Shiftan TA, Mendelsohn J. Hodgkin's disease and anergy. Blut 38(1):1-7, 1/1979.
de Vries JE, Caviles AP, Jr, Bont WS, Mendelsohn J. The role of monocytes in human
lymphocyte activation by mitogens. J Immunol 122(3):1099-107, 3/1979.
Mendelsohn J, Nordberg J. Adenylate cyclase in thymus-derived and bone marrow-derived
lymphocytes from normal donors and patients with chronic lymphocytic leukemia. J Clin
Invest 63(6):1124-32, 6/1979.
Page 8 of 38
John Mendelsohn, M.D.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Taetle R, Lane TA, Mendelsohn J. Drug-induced agranulocytosis: in vitro evidence for
immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. Blood
54(2):501-12, 8/1979.
Newman JG, Newman TB, Bowie LJ, Mendelsohn J. An examination of the role of vitamin E
in glucose-6-phosphate dehydrogenase deficiency. Clin Biochem 12(5):149-51, 10/1979.
de Vries JE, Mendelsohn J, Bont WS. The requirement for monocytes in spontaneous
cytotoxicity by lymphocytes from healthy donors and melanoma patients. International
Journal of Cancer 25(1):73-84, 1/1980.
Byfield JE, Barone R, Mendelsohn J, Frankel S, Quinol L, Sharp T, Seagren S. Infusional 5fluorouracil and X-ray therapy for non-resectable esophageal cancer. Cancer 45(4):703-8,
2/1980.
de Vries JE, Mendelsohn J, Bont WS. Requirement for monocytes in the spontaneous
cytotoxic effects of human lymphocytes against non-lymphoid target cells. Nature
283(5747):574-6, 2/1980.
Green MH, Brooks TL, Mendelsohn J, Howell SB. Antitumor activity of L-canavanine against
L1210 murine leukemia. Cancer Research 40(3):535-7, 3/1980.
Howell SB, Taetle R, Mendelsohn J. Thymidine as a chemotherapeutic agent: sensitivity of
normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia. Blood
55(3):505-10, 3/1980.
de Vries JE, Mendelsohn J, Bont WS. The role of target cells, monocytes, and Fc receptorbearing lymphocytes in human spontaneous cell-mediated cytotoxicity and antibodydependent cellular cytotoxicity. J Immunol 125(1):396-405, 7/1980.
Howell SB, Chu B, Mendelsohn J, Carson DA, Kung FH, Seegmiller JE. Thymidine as a
chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient
with T-cell acute lymphocytic leukemia. Journal of the National Cancer Institute 65(2):277-84,
8/1980.
Taetle R, Mendelsohn J. Modulation of normal and abnormal myeloid progenitor proliferation
by cyclic nucleotides and PGE1. Blood Cells 6(4):701-18, 1980.
De Vries JE, Vyth FA, Mendelsohn J. T-cell growth factor-mediated proliferation of
lymphocytes from a T-chronic lymphocytic leukaemia patient lacking mitogen and alloantigen
responsiveness. Clinical and Experimental Immunology 43(2):302-10, 2/1981.
Hudig D, Haverty T, Fulcher C, Redelman D, Mendelsohn J. Inhibition of human natural
cytotoxicity by macromolecular antiproteases. J Immunol 126(4):1569-74, 4/1981.
Howell SB, Chu BB, Wung WE, Metha BM, Mendelsohn J. Long-duration intracavitary
infusion of methotrexate with systemic leucovorin protection in patients with malignant
effusions. J Clin Invest 67(4):1161-70, 4/1981.
Hudig D, Djobadze M, Redelman D, Mendelsohn J. Active tumor cell resistance to human
natural killer lymphocyte attack. Cancer Research 41(7):2803-8, 7/1981.
Rice C, Hudig D, Newton RS, Mendelsohn J. Effect of unsaturated fatty acids on human
lymphocytes: disparate influences of oleic and linolenic acids on natural cytotoxicity. Clinical
Immunology and Immunopathology 20(3):389-401, 9/1981.
Taetle R, Mendelsohn J. An emerging role for prostaglandin E1 in regulation of
granulopoiesis. Leukemia Research 5(6):511-2, 1981.
Mendelsohn J, Hudig D, Castagnola J. DNA synthesis and proliferation of human
lymphocytes in vitro: III. Fate of cycling cells in aging cultures of phytohemagglutinin
stimulated human lymphocytes. Journal of Cellular Physiology 106(1):13-22, 1981.
Mendelsohn J, Howell SB. Thymidine (TdR) as a potential chemotherapeutic agent:
cytokinetic studies. Acta Pathologica et Microbiologica Scandinavica - Section A Pathology
89(Suppl.274):509-510, 1981.
Dillman RO, Taetle R, Seagren S, Royston I, Koziol J, Mendelsohn J. Extensive disease
small cell carcinoma of the lung: trial of non-cross resistant chemotherapy and consolidation
radiotherapy. Cancer 49(10):2003-8, 5/1982.
Young JA, Dillman RO, Seagren SL, Taetle R, Rentschler RE, Lea JW, Jr, Lehar TJ, Green
MR, Stanton W, Mendelsohn J, Royston I. Non-cross-resistant chemotherapy and
consolidation radiotherapy for small cell carcinoma of the lung. Cancer Treatment Reports
66(6):1399-401, 6/1982.
Page 9 of 38
John Mendelsohn, M.D.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
Taetle R, Richardson D, To D, Royston I, Mendelsohn J. Colony-forming assay for
circulating chronic lymphocytic leukemia cells. Leukemia Research 6(3):335-44, 1982.
Mendelsohn J, Rice J. Deconvolution of microfluorometic histograms with splines. J Am Stat
Assoc 77:748-753, 1982.
Dillman Ro, Beauregard JC, Mendelsohn J, Green MR, Howell SB, Royston I. Phase I trials
of thymosin fractions 5 and thymosin alpha 1. J Biol Response Modifiers 1:35-41, 1982.
Taetle R, To D, Caviles A, Norby SW, Mendelsohn J. Characterization of normal peripheral
blood lymphocyte colony-forming cells: cell cycle status, surface markers, and cellular growth
requirements. Blood 61(3):548-55, 3/1983.
Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431
cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth
factor by an anti-receptor monoclonal antibody. Proceedings of the National Academy of
Sciences of the United States of America 80(5):1337-41, 3/1983.
Mendelsohn J, Trowbridge I, Castagnola J. Inhibition of human lymphocyte proliferation by
monoclonal antibody to transferrin receptor. Blood 62(4):821-6, 10/1983.
Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro
of monoclonal antibodies to human epidermal growth factor receptors. Molecular Biology and
Medicine 1(5):511-29, 12/1983.
Rice C, Hudig D, Lad P, Mendelsohn J. Ethanol activation of human natural cytotoxicity.
Immunopharmacology 6(4):303-16, 12/1983.
Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human
tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Cancer Research 44(3):1002-7, 3/1984.
Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J.
Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal
growth factor binding and antagonists of epidermal growth factor binding and antagonists of
epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem
259(12):7755-60, 6/1984.
Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS, Gill GN. Relation of epidermal
growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J
Biol Chem 259(12):7761-6, 6/1984.
Fagnani R, Cooper HL, Mendelsohn J. Purification of human interleukin 2 to apparent
homogeneity and partial characterization of its receptor. Analytical Biochemistry 142(2):48796, 11/1984.
Taetle R, Rhyner K, Castagnola J, To D, Mendelsohn J. Role of transferrin, Fe, and
transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor
monoclonal antibody. J Clin Invest 75(3):1061-7, 3/1985.
Sunada H, MacLeod C, Mendelsohn J. A direct radioimmunoassay for human epidermal
growth factor receptor using 32P-autophosphorylated receptor. Analytical Biochemistry
149(2):438-47, 9/1985.
Yu AL, Mendelsohn J, Matsumoto S. Induction of Complete Remission in T-All by
Deoxycoformycin (Dcf) and Ara-A. Pediatric Research 19(7):783-783, 1985.
Gooi HC, Hounsell EF, Lax I, Kris RM, Libermann TA, Schlessinger J, Sato JD, Kawamoto T,
Mendelsohn J, Feizi T. The carbohydrate specificities of the monoclonal antibodies 29.1,
455 and 3C1B12 to the epidermal growth factor receptor of A431 cells. Biosci Rep 5(1):8394, 1985.
MacLeod CL, Luk A, Castagnola J, Cronin M, Mendelsohn J. EGF induces cell cycle arrest
of A431 human epidermoid carcinoma cells. Journal of Cellular Physiology 127(1):175-82,
4/1986.
Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin
receptor monoclonal antibodies. Cancer Research 46(4 Pt 1):1759-63, 4/1986.
Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal
growth factor receptor is internalized without stimulating receptor phosphorylation.
Proceedings of the National Academy of Sciences of the United States of America
83(11):3825-9, 6/1986.
Page 10 of 38
John Mendelsohn, M.D.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
Santon JB, Cronin MT, MacLeod CL, Mendelsohn J, Masui H, Gill GN. Effects of epidermal
growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer
Research 46(9):4701-5, 9/1986.
Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of
epidermal growth factor receptor in human cultured cells and tissues: relationship to cell
lineage and stage of differentiation. Cancer Research 46(9):4726-31, 9/1986.
Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for antiepidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer
Research 46(11):5592-8, 11/1986.
Yu AL, Mendelsohn J, Matsumoto SS. Induction of complete remission in T-cell acute
lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine
(ara-A). Advances in Experimental Medicine and Biology 195 Pt A:491-6, 1986.
Mendelsohn J, Masui H, Sunada H, Macleod C. Monoclonal-Antibodies to the Egf Receptor
Selectively Inhibit the Growth of Human-Tumor Cells. Journal of Cellular Biochemistry:40-40,
1986.
Vollmar AM, Banker DE, Mendelsohn J, Herschman HR. Toxicity of ligand and antibodydirected ricin A-chain conjugates recognizing the epidermal growth factor receptor. Journal of
Cellular Physiology 131(3):418-25, 6/1987.
Castagnola J, MacLeod C, Sunada H, Mendelsohn J, Taetle R. Effects of epidermal growth
factor on transferrin receptor phosphorylation and surface expression in malignant epithelial
cells. Journal of Cellular Physiology 132(3):492-500, 9/1987.
Sobol RE, Astarita RW, Hofeditz C, Masui H, Fairshter R, Royston I, Mendelsohn J.
Epidermal growth factor receptor expression in human lung carcinomas defined by a
monoclonal antibody. Journal of the National Cancer Institute 79(3):403-7, 9/1987.
Sunada H, Peacock J, Mendelsohn J. Effects of Cell-Culture Density on Expression and
Function of the Epidermal Growth-Factor Receptor. Cell Structure and Function 12(6):667667, 12/1987.
Sunada H, Peacock J, Mendelsohn J. A Possible Functional-Significance of Receptor
Phosphorylation in Processing of Internalized Egf Receptor. Journal of Cellular
Biochemistry:43-43, 1987.
Mendelsohn J, Masui H, Goldenberg A. Anti-epidermal growth factor receptor monoclonal
antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway.
Transactions of the Association of American Physicians 100:173-8, 1987.
Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J. Cytotoxic Effect of the Conjugate
of Anti-Egf Receptor Monoclonal-Antibody to Ricin a Chain on Human-Tumor Cells. Journal
of Cellular Biochemistry:36-36, 1987.
Yu PP, Sunada H, Peacock J, Mendelsohn J. Modulation of Epidermal Growth-Factor
Receptor (Egfr) Tyrosine Kinase-Activity Independent of Ligand Affinity State. Journal of
Cellular Biochemistry:49-49, 1987.
Mendelsohn J. Potential Antitumor-Activity of Monoclonal-Antibodies against the Epidermal
Growth-Factor Receptor. Investigational New Drugs 5(1):102-102, 1987.
Goldenberg A, Sunada H, Peacock J, Castagnola J, Mendelsohn J. Varying Effects of Egf
Upon Proliferation of Cultured A431 Cells. Journal of Cellular Biochemistry:26-26, 1987.
Palombella VJ, Mendelsohn J, Vilcek J. Mitogenic action of tumor necrosis factor in human
fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor.
Journal of Cellular Physiology 135(1):23-31, 4/1988.
Mendelsohn J. Anti-EGF receptor monoclonal antibodies: biological studies and potential
clinical applications. Transactions of the American Clinical and Climatological Association
100:31-8, 1988.
Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal
antibodies. Progress in Allergy 45:147-60, 1988.
Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J. Cytotoxicity against human tumor
cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody
to recombinant ricin A chain. Cancer Research 49(13):3482-8, 7/1989.
Kumar R, Mendelsohn J. Role of 2'-5'-oligoadenylate synthetase in gamma-interferonmediated growth inhibition of A431 cells. Cancer Research 49(18):5180-4, 9/1989.
Page 11 of 38
John Mendelsohn, M.D.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H,
Goldenberg A, Mendelsohn J, et al. Anti-epidermal growth factor receptor antibodies inhibit
the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol
3(11):1830-8, 11/1989.
Chen LL, Dean A, Jenkinson T, Mendelsohn J. Effect of transforming growth factor-beta 1
on proliferation and induction of hemoglobin accumulation in K-562 cells. Blood 74(7):236875, 11/1989.
Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human
tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor
monoclonal antibody. Journal of the National Cancer Institute 81(21):1616-25, 11/1989.
Mendelsohn J. Antiepidermal Growth-Factor (Egf) Receptor (R) Monoclonal-Antibodies
(Mabs) as Potential Anticancer Agents. European Journal of Cancer 26(2):160-160, 2/1990.
Sunada H, Yu P, Peacock JS, Mendelsohn J. Modulation of tyrosine, serine, and threonine
phosphorylation and intracellular processing of the epidermal growth factor receptor by
antireceptor monoclonal antibody. Journal of Cellular Physiology 142(2):284-92, 2/1990.
Manni A, Wright C, Badger B, Bartholomew M, Herlyn M, Mendelsohn J, Masui H, Demers
L. Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control
of experimental breast cancer growth in vitro by estradiol, prolactin, and progesterone. Breast
Cancer Research and Treatment 15(2):73-83, 2/1990.
Kumar R, Mendelsohn J. Growth regulation of A431 cells. Modulation of expression of
transforming growth factor-alpha mRNA and 2',5'-oligoadenylate synthetase activity. J Biol
Chem 265(8):4578-82, 3/1990.
Klein SB, Mendelsohn J, Vorhees JJ, Elder JT. Tgf-Alpha Autoinduction Requires Egf
Receptor Activation. Journal of Investigative Dermatology 94(4):543-543, 4/1990.
Ciardiello F, McGeady ML, Kim N, Basolo F, Hynes N, Langton BC, Yokozaki H, Saeki T,
Elliott JW, Masui H, Mendelsohn J, Soule H, Russo J, Salomon DS. Transforming Growth
Factor-Alpha Expression Is Enhanced in Human Mammary Epithelial-Cells Transformed by
an Activated C-Ha-Ras Protooncogene but Not by the C-Neu Protooncogene, and
Overexpression of the Transforming Growth Factor-Alpha Complementary-DNA Leads to
Transformation. Cell Growth & Differentiation 1(9):407-420, 9/1990.
Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibodies as potential
anti-cancer agents. J Steroid Biochem Mol Biol 37(6):889-92, 12/1990.
Bates SE, Valverius EM, Ennis BW, Bronzert DA, Sheridan JP, Stampfer MR, Mendelsohn
J, Lippman ME, Dickson RB. Expression of the transforming growth factor-alpha/epidermal
growth factor receptor pathway in normal human breast epithelial cells. Endocrinology
126(1):596-607, 1990.
Kumar R, Shepard HM, Mendelsohn J. Regulation of phosphorylation of the c-erbB-2/HER2
gene product by a monoclonal antibody and serum growth factor(s) in human mammary
carcinoma cells. Mol Cell Biol 11(2):979-86, 2/1991.
Van de Vijver MJ, Kumar R, Mendelsohn J. Ligand-induced activation of A431 cell
epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon
receptors on the surface rather than intracellularly. J Biol Chem 266(12):7503-8, 4/1991.
Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous
growth of androgen-independent human prostatic carcinoma cells: role of transforming
growth factor alpha. Cancer Research 51(11):2780-5, 6/1991.
Goldkorn T, Dressler KA, Muindi J, Radin NS, Mendelsohn J, Menaldino D, Liotta D,
Kolesnick RN. Ceramide stimulates epidermal growth factor receptor phosphorylation in
A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine
action. J Biol Chem 266(24):16092-7, 8/1991.
Mendelsohn J. Cancer biology: Editorial overview. Current Opinion in Oncology 3(1):63-64,
1991.
Sunada H, Peacock J, Mendelsohn J. Ligand induced internalization of epidermal growth
factor receptors by A431 cells decreases at high cell densities in culture. Growth Factors
5(1):45-55, 1991.
Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M,
Larson SM, Mendelsohn J. Phase I and imaging trial of indium 111-labeled anti-epidermal
Page 12 of 38
John Mendelsohn, M.D.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
growth factor receptor monoclonal antibody 225 in patients with squamous cell lung
carcinoma. Journal of the National Cancer Institute 83(2):97-104, 1991.
Karnes WE, Jr, Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Park JG,
Cuttitta F. Autonomous proliferation of colon cancer cells that coexpress transforming growth
factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology
102(2):474-85, 2/1992.
Goldkorn T, Mendelsohn J. Transforming growth factor beta modulates phosphorylation of
the epidermal growth factor receptor and proliferation of A431 cells. Cell Growth Differ
3(2):101-9, 2/1992.
Klein SB, Fisher GJ, Jensen TC, Mendelsohn J, Voorhees JJ, Elder JT. Regulation of TGFalpha expression in human keratinocytes: PKC-dependent and -independent pathways.
Journal of Cellular Physiology 151(2):326-36, 5/1992.
Galberoglio C, Cordoncardo C, Sorvillo J, Casper ES, Houghton AN, Mendelsohn J,
Brennan MF. Expression of Epidermal Growth-Factor Receptor and Transforming Growth
Factor-Alpha in Human Myogenic Sarcomas. Journal of Experimental and Clinical Cancer
Research 11(2):83-91, 6/1992.
Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human
renal carcinoma cells: role of transforming growth factor alpha. Cancer Research
52(12):3335-9, 6/1992.
Goldkorn T, Haimovitzfriedman A, Balaban N, Mendelsohn J, Fuks Z. Radiation Modulation
of Epidermal Growth-Factor Receptor Phosphorylation in A431 Cells - Evidence That
Radiation Modulates Signal Transduction. Molecular Biology of the Cell 3:A147-A147,
9/1992.
Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor
receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces
autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor
necrosis factor alpha. Cancer Research 52(21):5887-92, 11/1992.
Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor
monoclonal antibodies. Journal of the National Cancer Institute. Monographs.(13):125-31,
1992.
Goldkorn T, Haimovitz A, Balaban N, Mendelsohn J, Fuks Z. Signal Transduction
Modulation by Radiation of A431 Cells. FASEB Journal 7(4):A805-A805, 2/1993.
Chen LL, Narayanan R, Hibbs MS, Benn PA, Clawson ML, Lu G, Rhim JS, Greenberg B,
Mendelsohn J. Altered epidermal growth factor signal transduction in activated Ha-rastransformed human keratinocytes. Biochemical and Biophysical Research Communications
193(1):167-74, 5/1993.
Scott AM, Baselga J, Divgi CR, Pfister D, Kris M, Zhang JJ, Daghighian F, Carmichael N,
Oettgen HF, Larson SM, Mendelsohn J. Comparison of Phase-I Trials of Antiepidermal
Growth-Factor Receptor (Egfr) Monoclonal-Antibodies (Mabs) 528 and 225 Labeled with I131 and in-111. Journal of Nuclear Medicine 34(5):P213-P213, 5/1993.
Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Jr, Mendelsohn J.
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor
monoclonal antibodies. Journal of the National Cancer Institute 85(16):1327-33, 8/1993.
Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor
function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor
monoclonal antibodies. Cancer Research 53(18):4322-8, 9/1993.
Stampfer MR, Pan CH, Hosoda J, Bartholomew J, Mendelsohn J, Yaswen P. Blockage of
EGF receptor signal transduction causes reversible arrest of normal and immortal human
mammary epithelial cells with synchronous reentry into the cell cycle. Experimental Cell
Research 208(1):175-88, 9/1993.
Chen LL, Gansbacher B, Gilboa E, Taetle R, Oval J, Hibbs MS, Huang CK, Clawson ML,
Bilgrami S, Schlessinger J, Mendelsohn J. Retroviral Gene-Transfer of Epidermal GrowthFactor Receptor into Hl-60 Cells Results in a Partial Block of Retinoic Acid-Induced
Granulocytic Differentiation. Cell Growth & Differentiation 4(9):769-776, 9/1993.
Page 13 of 38
John Mendelsohn, M.D.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor
receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431
cell xenografts. Cancer Research 53(19):4637-42, 10/1993.
Fan Z, Mendelsohn J, Masui H, Kumar R. Regulation of epidermal growth factor receptor in
NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem 268(28):21073-9,
10/1993.
Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of
chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model
for human melanoma. Cancer Immunol Immunother 37(5):343-9, 10/1993.
Meyers MB, Yu P, Mendelsohn J. Crosstalk between epidermal growth factor receptor and
P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. Biochemical
Pharmacology 46(10):1841-8, 11/1993.
Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Mechanisms of cellular
cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma
cells. Immunology Letters 39(1):91-9, 12/1993.
Masui H, Castro L, Mendelsohn J. Consumption of EGF by A431 cells: evidence for receptor
recycling. J Cell Biol 120(1):85-93, 1993.
Kumar R, Mendelsohn J. Reduced expression of c-erbB2 gene product in human mammary
carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
Anticancer Research 14(3A):1001-8, 5/1994.
Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer
therapy. Pharmacol Ther 64(1):127-54, 10/1994.
Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor
dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.
J Biol Chem 269(44):27595-602, 11/1994.
Sturgis EM, Sacks PG, Masui H, Mendelsohn J, Schantz SP. Effects of antiepidermal
growth factor receptor antibody 528 on the proliferation and differentiation of head and neck
cancer. Otolaryngol Head Neck Surg 111(5):633-43, 11/1994.
Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J,
Mendelsohn J, Miller WH, Jr. 9-Cis retinoic acid inhibits growth of breast cancer cells and
down-regulates estrogen receptor RNA and protein. Cancer Research 54(24):6549-56,
12/1994.
Baselga J, Norton L, Coplan K, Shalaby R, Mendelsohn J. Anti-Growth Factor-Receptor
Monoclonal-Antibodies Enhance the Antitumor Effects of Paclitaxel in Breast-Cancer
Xenografts. Journal of Cellular Biochemistry:250-250, 1994.
Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn
J, Groner B, Hynes NE. EGF receptor and p185erbB-2-specific single-chain antibody toxins
differ in their cell-killing activity on tumor cells expressing both receptor proteins. International
Journal of Cancer 60(1):137-44, 1/1995.
Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, Tagliaferri P,
Baselga J, Mendelsohn J, Bianco AR, et al. Cooperative antiproliferative effects of 8-chlorocyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human
cancer cells. Clin Cancer Res 1(2):161-7, 2/1995.
Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal
growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its
delay by insulin. J Clin Invest 95(4):1897-905, 4/1995.
Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn
J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor
and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer
Res 1(5):545-50, 5/1995.
Mendelsohn J. Editorial. Clin Cancer Res 1(7):675, 7/1995.
Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of
epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis
16(8):1741-5, 8/1995.
Page 14 of 38
John Mendelsohn, M.D.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH, Jr.
Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7
breast cancer cells. Journal of Cellular Physiology 165(1):212-21, 10/1995.
Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, Mendelsohn J. Prolonged induction of
p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation
mediates ligand-induced A431 cell growth inhibition. J Cell Biol 131(1):235-42, 10/1995.
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a
chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Clin Cancer Res 1(11):1311-8, 11/1995.
Baselga J, Mendelsohn J, Kim YM, Pandiella A. Autocrine regulation of membrane
transforming growth factor-alpha cleavage. J Biol Chem 271(6):3279-84, 2/1996.
Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B,
Mendelsohn J, Koff A. Formation of p27-CDK complexes during the human mitotic cell
cycle. Cell Growth Differ 7(2):135-46, 2/1996.
Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora
G, Bianco AR, Mendelsohn J, Salomon DS, Ciardiello F. Growth inhibition of human colon
carcinoma cells by combinations of anti-epidermal growth factor-related growth factor
antisense oligonucleotides. Clin Cancer Res 2(3):601-9, 3/1996.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT,
Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II
study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in
patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):737-44,
3/1996.
Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human
hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion
proteins. Proceedings of the National Academy of Sciences of the United States of America
93(7):2702-7, 4/1996.
Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC. Involvement of B lymphocytes
in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by
an antibody-lymphotoxin fusion protein. Cancer Research 56(8):1707-12, 4/1996.
Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J. Involvement of p27KIP1
in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.
Oncogene 12(7):1397-403, 4/1996.
Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor
receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic
cancer cell line DU145. Cancer Research 56(16):3666-9, 8/1996.
Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI.
The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human
prostate carcinoma. J Immunother Emphasis Tumor Immunol 19(6):419-27, 11/1996.
Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S,
Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of combined blockade of epidermal
growth factor receptor and protein kinase A. Journal of the National Cancer Institute
88(23):1770-6, 12/1996.
Wang H, Rubin M, Fenig E, DeBlasio A, Mendelsohn J, Yahalom J, Wieder R. Basic
fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while
inducing both mitogenic and inhibitory G1 events. Cancer Research 57(9):1750-7, 5/1997.
Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M, Deisseroth AB. Expression
of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical
carcinoma cells. Journal of the National Cancer Institute 89(17):1271-6, 9/1997.
Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase
inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer
cells in a receptor number-dependent manner. Clin Cancer Res 3(11):2099-106, 11/1997.
Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. Reciprocal changes in p27(Kip1) and
p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth
factor receptors. Clin Cancer Res 3(11):1943-8, 11/1997.
Page 15 of 38
John Mendelsohn, M.D.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction
between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian
cells. J Biol Chem 273(3):1568-73, 1/1998.
Kumar R, Mandal M, Adam L, Bandyopadhyay D, Steinbach G, Mendelsohn J, Vadlamudi
R. Activation of HER2 pathway induces expression of cyclooxygenase-2, release of
prostaglandin E2, and mitogenesis in human colorectal cancer cells. Gastroenterology
114(4):A631-A631, 4/1998.
Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S,
Mendelsohn J, Tortora G. Cooperative inhibition of renal cancer growth by anti-epidermal
growth factor receptor antibody and protein kinase A antisense oligonucleotide. Journal of
the National Cancer Institute 90(14):1087-94, 7/1998.
Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JE, Jr. Epidermal growth factorinduced growth inhibition requires Stat1 activation. Cell Growth Differ 9(7):505-12, 7/1998.
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized antiHER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin
against HER2/neu overexpressing human breast cancer xenografts. Cancer Research
58(13):2825-31, 7/1998.
Bast RC, Jr, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn
J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth
factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma
17(4):313-21, 8/1998.
Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in
human colorectal cancer cells. Oncogene 17(8):999-1007, 8/1998.
Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn
J, Bast RC, Jr. Cell surface density of p185(c-erbB-2) determines susceptibility to antip185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with antip170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res 4(10):2545-50, 10/1998.
Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin
regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1
via phosphatidylinositol-3 kinase. J Biol Chem 273(43):28238-46, 10/1998.
Mendelsohn J. Blockade of signal transduction as anti-cancer therapy. Annals of Oncology
9:18-18, 1998.
Ciardiello F, Caputo R, Bianco R, Pomatico G, Bianco AR, Agrawal S, Mendelsohn J,
Tortora G. Inhibition of renal cancer growth by C225 anti-epidermal growth factor receptor
monoclonal antibody and protein kinase A mixed backbone antisense oligonucleotide. Annals
of Oncology 9:81-81, 1998.
Tortora G, Damiano V, Bianco R, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello
F. Synergistic antitumor effect by novel modified oligonucleotides targeting PKAI combined
with cytotoxic drugs or monoclonal antibodies. Annals of Oncology 9:126-126, 1998.
Tortora G, Caputo R, Damiano V, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello
F. Synergistic antitumor effect of novel mixed backbone oligonucleotides targeting protein
kinase A in combination with cytotoxic drugs or biological agents. Annals of Oncology 9:8181, 1998.
Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced
growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene
18(3):731-8, 1/1999.
Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of
cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18(2):305-14, 1/1999.
Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z,
Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with
topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer
Res 5(4):909-16, 4/1999.
Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello
F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein
kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on
human breast cancer cell growth. Clin Cancer Res 5(4):875-81, 4/1999.
Page 16 of 38
John Mendelsohn, M.D.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized antiHER2 antibody (Herceptin (TM)) enhances the antitumor activity of paclitaxel and doxorubicin
against HER2/neu overexpressing human breast cancer xenografts (vol 58, pg 2825, 1998).
Cancer Research 59(8):2020-2020, 4/1999.
Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn J. Constitutive overexpression of
cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation
of epidermal growth factor. Breast Cancer Research and Treatment 55(3):267-83, 6/1999.
Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclindependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA
PCa 2b prostate cancer cells. Clin Cancer Res 5(8):2171-7, 8/1999.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT,
Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II
study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neuoverexpressing metastatic breast cancer. Seminars in Oncology 26(4 Suppl 12):78-83,
8/1999.
Ciardiello F, Bianco R, Damiano V, Caputo R, De Placido S, Fontanini G, Agrawal S,
Mendelsohn J, Bianco AR, Tortora G. Antiangiogenic and antitumor effect of VEGF
antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in
human colon cancer. European Journal of Cancer 35:S103-S103, 9/1999.
Normanno N, Tortora G, De Luca A, Pomatico G, Casamassimi A, Agrawal S, Mendelsohn
J, Bianco AR, Ciardiello F. Synergistic growth inhibition and induction of apoptosis by a novel
mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 antiEGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep
6(5):1105-9, 9/1999.
Vadlamudi R, Adam L, Talukder A, Mendelsohn J, Kumar R. Serine phosphorylation of
paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase. Oncogene
18(51):7253-64, 12/1999.
Mendelsohn J. Editorial. Clinical Cancer Research 5(1):1-1, 1999.
Schumacher G, Fan Z, Mendelsohn J, Bechstein WO, Roth JA. Wild-type p53 up-regulates
the tumor suppressor gene p27(KIP1) which results in enhanced induction of apoptosis.
Langenbecks Archives of Surgery:531-535, 1999.
Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. In
vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor
antibody. Clin Cancer Res 6(2):701-8, 2/2000.
Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A,
Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of
anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with
cisplatin. J Clin Oncol 18(4):904-14, 2/2000.
Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z. Differential modulation of paclitaxelmediated apoptosis by p21Waf1 and p27Kip1. Oncogene 19(20):2423-9, 5/2000.
Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation
of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon
cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 82(12):1991-9,
6/2000. PMCID: PMC2363248.
Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE. Reduced growth rate
accompanied by aberrant epidermal growth factor signaling in drug resistant human breast
cancer cells. Biochimica et Biophysica Acta 1497(2):215-26, 7/2000.
Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S,
Bianco AR, Mendelsohn J, Tortora G. Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular
endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin
Cancer Res 6(9):3739-47, 9/2000.
Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De
Placido S, Bianco AR, Ciardiello F. Antitumor activity of combined treatment of human cancer
cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody
Page 17 of 38
John Mendelsohn, M.D.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6(11):4343-50,
11/2000.
Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular
endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates
heregulin-beta1-mediated angiogenesis. J Biol Chem 275(50):39451-7, 12/2000.
Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Involvement of p21Waf1 in
mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB468 human breast cancer cells. Anticancer Research 20(1A):103-11, 2000.
Talukder AH, Jorgensen HF, Mandal M, Mishra SK, Vadlamudi RK, Clark BF, Mendelsohn
J, Kumar R. Regulation of elongation factor-1alpha expression by growth factors and antireceptor blocking antibodies. J Biol Chem 276(8):5636-42, 2/2001.
Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, Bagheri-Yarmand R, Mendelsohn
J, Kumar R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression
and function. J Biol Chem 276(13):9699-704, 3/2001.
Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth
factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth
factor receptor monoclonal antibody. Oncogene 20(15):1913-22, 4/2001.
Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR,
Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK.
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with
head and neck cancer. Clin Cancer Res 7(5):1204-13, 5/2001.
Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J,
Bianco AR, Tortora G. Antisense oligonucleotides targeting the epidermal growth factor
receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human
cancer cell lines. International Journal of Cancer 93(2):172-8, 7/2001.
Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J,
Rosello J, Nicholson RI, Mendelsohn J, Baselga J. Activated extracellular signal-regulated
kinases: association with epidermal growth factor receptor/transforming growth factor alpha
expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth
factor receptor treatments. Cancer Research 61(17):6500-10, 9/2001.
Knuefermann C, Lu Y, Wu L, Schmidt M, Mendelsohn J, Fan Z. Role of AKT in
chemotherapy-mediated cytotoxicity in MCF-7 breast cancer cells. Breast Cancer Research
and Treatment 69(3):275, 2001.
Mendelsohn J. Combining kinase inhibitors with chemotherapy. European Journal of Cancer
38:S3-S3, 11/2002.
Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J,
Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast
adenocarcinoma cells. Oncogene 22(21):3205-12, 5/2003.
Mendelsohn J. Growth factors, hormones, cell growth, surgery, subspecialty investigation: A
message from the editor-in-chief. Clinical Cancer Research 9(10 I):3517, 2003.
Mendelsohn J. Merging medicine with science: the birth of a targeted therapy in cancer. Ann
Acad Med Singapore 33(5 Suppl):S3, 9/2004.
Mendelsohn J. EGF Receptors as a Target for Cancer therapy. Trans Am Clin Climatol
Assoc 115:249-54, 2004. PMCID: PMC2263769.
Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M,
Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS,
Kasler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, MartinMoreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T,
Potschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V,
Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D,
Zatonski W, Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco
Day. Lancet 365(9476):1990-2, 6/2005.
Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor
monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to
transcriptional inhibition of vascular endothelial growth factor expression. Oncogene
24(27):4433-41, 6/2005.
Page 18 of 38
John Mendelsohn, M.D.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
Mendelsohn J. Targeting the EGF receptor: Experience and lessons. Ejc Supplements
4(6):25-26, 6/2006.
Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: Advanced tools for
"tailored" therapy? Proceedings of the National Academy of Sciences of the United States of
America 103(46):17073-4, 11/2006.
Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth
factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping
treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Research 67(17):82407, 9/2007.
Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor
receptor monoclonal antibody cetuximab. Mol Cancer Ther 7(5):1207-17, 5/2008.
Cardó-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W,
Pasqualini R. From combinatorial peptide selection to drug prototype (II): targeting the
epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A 107(11):5118-23,
3/2010. e-Pub 2/2010. PMCID: PMC2841862.
Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X,
Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human
erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated
Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 11/2010. PMCID:
PMC3022383.
Mendelsohn J. A national cancer clinical trials system for targeted therapies. Sci Transl Med
3(75):75cm8, 3/2011.
Mendelsohn J, Tursz T, Schilsky RL, Lazar V. WIN Consortium--challenges and advances.
Nat Rev Clin Oncol 8(3):133-4, 3/2011.
Ram PT, Mendelsohn J, Mills GB. Bioinformatics and systems biology. Mol Oncol 6(2):14754, 4/2012. e-Pub 2/2012. PMCID: PMC3345061.
Mendelsohn J, Ringborg U, Schilsky RL. Personalized cancer medicine - a strategy to
counteract an increasing cancer challenge. Mol Oncol 6(2):109-10, 4/2012. e-Pub 3/2012.
Farhangfar CJ, Meric-Bernstam F, Mendelsohn J, Mills GB, Lucio-Eterovic AK. The impact
of tumor heterogeneity on patient treatment decisions. Clin Chem 59(1):38-40, 1/2013. e-Pub
11/2012.
Invited Articles
1. Sell S, Mendelsohn J. Transfer of specific immunity with RNA. Arch Pathol Lab Med
102:217-222, 5/1978.
2. Taetle R, To D, Mendelsohn J. In vitro sensitivity to steroid hormones and cytotoxic agents
of normal and malignant lymphocyte colony-forming cells. Cancer Research 43:3553-3558,
8/1983.
3. Gabrilove J, Mendelsohn J. Growth factors in human cancer. Current Opinion in Oncology
2:163-170, 2/1990.
4. Mendelsohn J. The epidermal growth factor receptor as a target for therapy with antireceptor
monoclonal antibodies. Semin Cancer Biol 1:339-344, 10/1990.
5. Kumar R, Mendelsohn J. Polypeptide growth factors in the regulation of human tumor cell
proliferation. Current Opinion in Oncology 3:70-74, 2/1991.
6. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in
breast carcinoma. Breast Cancer Research and Treatment 29:127-138, 1994.
7. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J,
Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, et al. Tumor receptor imaging:
proceedings of the National Cancer Institute workshop, review of current work, and
prospective for further investigations. Clin Cancer Res 1:921-932, 8/1995.
8. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands
as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7:133-141, 8/1996.
9. Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J, Scher HI.
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.
Seminars in Oncology 23:41-48, 12/1996.
Page 19 of 38
John Mendelsohn, M.D.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Baselga J, Mendelsohn J. Type I receptor tyrosine kinases as targets for therapy in breast
cancer. Journal of Mammary Gland Biology and Neoplasia 2:165-174, 4/1997.
Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as
anticancer therapy. Clin Cancer Res 3:2703-2707, 12/1997.
Mendelsohn J. Book Review - Matters of life and death: Perspectives on public health,
molecular biology, cancer, and the prospects for the human race. Nat Med 4:465-466, 1998.
Mendelsohn J. EGF receptor blockade as anticancer therapy. Cancer Research Therapy
and Control 7:195-197, 1998.
Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies.
Current Opinion in Oncology 10:67-73, 1998.
Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy--the fourth
annual Joseph H Burchenal American Association of Cancer Research Clinical Research
Award Lecture. Clin Cancer Res 6:747-753, 3/2000.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene
19(56):6550-6565, 12/2000.
Mendelsohn J. Jeremiah Metzger Lecture. Targeted cancer therapy. Transactions of the
American Clinical and Climatological Association 111:95-110; discussion 110-111, 2000.
Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr
Relat Cancer 8:3-9, 3/2001.
Mendelsohn J, Dinney CP. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal
growth factor receptors as anticancer therapy. J Urol 165:1152-1157, 4/2001.
Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin
Oncol 20:1S-13S, 9/2002.
Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from
the laboratory to the clinic. Cancer Immunol Immunother 52:342-346, 5/2003.
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the
biology and treatment of cancer. J Clin Oncol 21:2787-2799, 7/2003.
Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Cancer
Treatment and Research 115:19-72, 2003.
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin
Oncol 33(4):369-385, 8/2006.
Editorials
1. Mendelsohn J. Immunotoxins: prospects and problems. J Clin Oncol 9:2088-2090, 12/1991.
2. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization.
Journal of the National Cancer Institute 89:341-343, 3/1997.
3. Mendelsohn J. Use of an antibody to target geldanamycin. Journal of the National Cancer
Institute 92:1549-1551, 10/2000.
4. Mendelsohn J. New feature: "The Cooperative Group Bulletin Board". Clin Cancer Res
7:1107, 2001.
5. Mendelsohn J. Moving discovery into clinical practice. Clinical Cancer Research 10:8129,
2004.
6. Mendelsohn J. Personalizing Oncology: Perspectives and Prospects. Journal of Clinical
Oncology. Submitted.
Other Articles
N/A
Abstracts
1. Salzman NP, Moore DE, Mendelsohn J. Isolation and characterization of human metaphase
chromosomes. Proceedings of the National Academy of Sciences of the United States of
America 56(5):1449-56, 11/1966.
2. Mendelsohn J, Parmer RJ, Multer MM. Altered Cyclic-Amp Metabolism in Chronic
Lymphocytic Leukemia Lymphocytes. Blood 46(6):1044-1044, 1975.
3. Bernheim JL, Mendelsohn J. Kinetics of DNA-Synthesis in Human Lymphocytes Stimulated
by Phytohemagglutinin (Pha). Clinical Research 23(3):A401-A401, 1975.
Page 20 of 38
John Mendelsohn, M.D.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
Bernheim J, Dorian R, Kelley M, Mendelsohn J. Kinetics of DNA synthesis, cell proliferation
and cell death in human lymphocyte stimulation by phytohemagglutinin (PHA). Federation
Proceedings 35(3), 1976.
Mendelsohn J, Castagnola J, Bernheim J. Evidence That DNA Synthesized by Stimulated
Lymphocytes Represents Only Semiconservative Premitotic Genome Replication.
Scandinavian Journal of Immunology 6(6-7):728-728, 1977.
Bernheim J, Dorian R, Mendelsohn J. Kinetics of Lymphocyte-Response to Pha and Ppd Effects of Cell Density and Balance of DNA-Synthesis and Mitosis. Scandinavian Journal of
Immunology 6(6-7):681-681, 1977.
Shiftan TA, Caviles AP, Mendelsohn J. Mechanisms of Depressed Cellular Immunity in
Hodgkins-Disease. Proceedings of the American Association for Cancer Research
18(MAR):307-307, 1977.
Bernheim J, Dorian R, Djobadze M, Mendelsohn J. Pitfalls in Lymphocyte Blastic
Transformation Assay - Variations in Proliferation Kinetics and Cold Thymidine (Tdr) Pools.
Scandinavian Journal of Immunology 6(6-7):680-681, 1977.
Dorian R, Mendelsohn J, Bernheim JL. Quantitation of Entry into and Exit from Cell-Cycle Analytical Method without Pharmacological Perturbation. Scandinavian Journal of
Immunology 6(6-7):691-692, 1977.
Mendelsohn J, Nordberg J. Adenyl-Cyclase in Normal and Leukemic Human Lymphocytes
(L). Clinical Research 26(3):A536-A536, 1978.
Byfield JE, Barone R, Seagren S, Frankel S, Quinol L, Mendelsohn J. Biweekly Infusional 5Fluorouracil (5-Fu) and X-Rays in Advanced Gastrointestinal Cancer (Gica). Proceedings of
the American Association for Cancer Research 19(MAR):322-322, 1978.
Mendelsohn J, Devries JE, Bont WS, Rumke P. Role of Monocytes in Spontaneous
Cytotoxic Effects of Human Lymphocytes. Proceedings of the American Association for
Cancer Research 19(MAR):210-210, 1978.
Mendelsohn J, Howell SB, Brooks TC, Nordberg J, Green MH. Cytotoxic and Anti-Tumor
Activity of Canavanine (Cana). Proceedings of the American Association for Cancer
Research 20(MAR):260-260, 1979.
Haverty T, Hudig D, Fulcher C, Redelman D, Mendelsohn J. Inhibition of Human Natural
Killer Activity by Low M. Wt. and Macromolecular Anti-Proteinases. Federation Proceedings
38(3):1176-1176, 1979.
Hudig D, Caviles AP, Mendelsohn J. Invitro Activation of Human Natural Cytotoxicity.
Federation Proceedings 38(3):1278-1278, 1979.
Taetle R, Mendelsohn J, Howell SB. Nucleoside Requirements for the Protection of Human
Marrow from Methotrexate (Mtx). Proceedings of the American Association for Cancer
Research 20(MAR):399-399, 1979.
Chan P, Byfield J, Barone R, Mendelsohn J, Frankel S, Hornbeck C, Griffiths J, Quinol L,
Campbell T, Sharp T. Radiosensitization (Rs) of Human-Tumors by 5-Fu Infusions and XRay Therapy (Xrt) - Phase-I and Pharmacokinetic Data. Proceedings of the American
Association for Cancer Research 20(MAR):246-246, 1979.
Howell SB, Chu B, Mendelsohn J, Taetle R, Carson DA, Seegmiller JE. Thymidine (Tdr) as
a Chemotherapeutic Agent - Pharmacologic, Cytokinetic and Biochemical-Studies in a Child
with T Cell Acute Lymphatic-Leukemia. Clinical Research 27(2):A387-A387, 1979.
Taetle R, Norby SW, Guittard JP, Mendelsohn JM, McCulloch EA. Cell-Cell Interactions in
Invitro Leukemic Blast Progenitor Proliferation. Proceedings of the American Association for
Cancer Research 21(MAR):57-57, 1980.
Djobadze M, Hudig D, Redelman D, Mendelsohn J. Failure of Cycloheximide to Inhibit
Human Natural Cyto-Toxicity to Both Fast and Slow Tumor Target-Cells. Federation
Proceedings 39(3):934-934, 1980.
Taetle R, Howell S, Koessler A, Mendelsohn J. Growth of Tumor Colony-Forming-Units from
Human-Tumor Xenografts - Potential Applications. Proceedings of the American Association
for Cancer Research 21(MAR):331-331, 1980.
Hudig D, Redelman D, Mendelsohn J. Inhibition of Human Natural Cyto-Toxicity by
Proteinase Substrates. Federation Proceedings 39(3):359-359, 1980.
Page 21 of 38
John Mendelsohn, M.D.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
Mendelsohn J, Castagnola J, Hudig D. Proliferating Lymphocytes Arrest in S-Phase and G2Phase in Increasing Numbers During Culture and Die in All Phases of the Cell-Cycle. Cell
and Tissue Kinetics 13(6):676-676, 1980.
Mendelsohn J, Vythdreese FA, Devries JE. T-Cell Growth Factor-Induced Proliferation of
Non-Responsive Human T-Chronic Lymphocyte Leukemia-Cells. Clinical Research
28(2):A495-A495, 1980.
Mendelsohn J, Richardson D, Taetle R, Royston I. Culture of Chronic LymphocyticLeukemia B-Cell Colonies. Clinical Research 29(2):A549-A549, 1981.
Mendelsohn J, Taetle R, Richardson D, Royston I. Culture of Normal and Leukemic HumanLymphocyte Colonies. Proceedings of the American Association for Cancer Research
22(MAR):368-368, 1981.
Rice C, Hudig D, Redelman D, Mendelsohn J. Effects of Unsaturated Fatty-Acids and
Ethanol on Human-Lymphocyte Natural Cyto-Toxicity (Nk). Federation Proceedings
40(3):1043-1043, 1981.
Streifel JA, Mendelsohn J, Howell SB. Modulation of cytosine arabinoside triphosphate (araCTP) and trinucleotide pools in a human acute leukemia cell line (HL-60) by thymidine (dThd)
and hydroxyurea (HU). Proceedings of the American Association for Cancer Research Vol.
22:844, 1981.
Mendelsohn J, To D, Taetle R. Characterization and drug treatment of human lymphocytes
in a colony assay. Proceedings of the American Society of Clinical Oncology Vol. 1, 1982.
Fagnani R, Mendelsohn J, Cooper HL. Purification of Human Interleukin-2 by AffinityChromatography. Federation Proceedings 41(3):564-564, 1982.
Fagnani R, Mendelsohn J. Purification of Human Interleukin-2 by Amicon Blue-a Gel AffinityChromatography. Immunobiology 163(2-4):388-388, 1982.
Demaertelaer V, Brambilla E, Mendelsohn J, Naaktgeboren N, Bernheim J. Rate of DNASynthesis as a Function of Cell Age DNA Content from Combined Microspectrofluorometric
and Autoradiographic Data. Cell and Tissue Kinetics 15(1):101-102, 1982.
Mendelsohn J, Taetle R, Castagnola J, Trowbridge I. A Monoclonal-Antibody to the
Receptor for Transferrin Can Inhibit Proliferation of Human-Lymphocytes. Clinical Research
31(2):A319-A319, 1983.
Kawamoto T, Sato JD, Le A, Polikoff J, Sato G, Mendelsohn J. High-Affinity Epidermal
Growth-Factor Receptors Detected by Monoclonal-Antibodies to the Receptor. Proceedings
of the American Association for Cancer Research 24(MAR):225-225, 1983.
Mendelsohn J, Kawamoto T, Sato JD, Sato G, Masui H. Growth-Inhibition of A431
Carcinoma in Athymic Mice by Anti-Egf Receptor Monoclonal-Antibodies. Proceedings of the
American Association for Cancer Research 25(MAR):275-275, 1984.
Sunada H, Masui H, Macleod C, Mendelsohn J. A Direct Radioimmune Assay for Human
Egf Receptor. Federation Proceedings 44(6):1831-1831, 1985.
Mendelsohn J, Masui H, Macleod C. Anti-Egf Receptor Monoclonal-Antibody 528 Inhibits
Proliferation of a Subset of Human-Tumor Cells in Culture and in Xenografts. Proceedings of
the American Association for Cancer Research 26(MAR):287-287, 1985.
Real FX, Rettig WJ, Mendelsohn J, Old LJ. Detection of Epidermal Growth-Factor Receptor
(Egfr) on Cultured Human Cell Using Monoclonal-Antibodies (Mabs) - Egfr Is a Differentiation
Antigen (Ag) of Cultured Melanoma. Federation Proceedings 44(3):549-549, 1985.
Mendelsohn J, Masui H, Macleod C. Monoclonal-Antibodies to the Egf Receptor Selectively
Inhibit the Growth of Human-Tumor Cells. Federation Proceedings 44(6):1863-1863, 1985.
Taetle R, Rhyner K, Castagnola J, Bering H, Mendelsohn J. The Relationship between
Transferrin Receptor (Tfr) Display, Cell Ferritin (Ferr), and Differentiation in MyeloidLeukemia Cells. Clinical Research 33(1):A49-A49, 1985.
Taetle R, Castagnola J, Mendelsohn J. The Roles of Transferrin (Tf), Transferrin Receptors
(Tfr) and Fe in Hematopoietic-Cell Growth - Receptor-Ligand Interactions in the Presence of
an Anti-Receptor Antibody (Ab). Proceedings of the American Association for Cancer
Research 26(MAR):278-278, 1985.
Masui H, Moroyama T, Mendelsohn J. Antiepidermal Growth-Factor (Egf) Receptor
Monoclonal-Antibodies (Mabs) with Different Isotypes Can Exert Antitumor-Activity by
Page 22 of 38
John Mendelsohn, M.D.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Different Mechanisms. Proceedings of the American Association for Cancer Research
27:338-338, 3/1986.
Goldenberg A, Sunada H, Mendelsohn J. Egf-Dependent Growth of A431 Cells in Collagen
Gel Culture. Proceedings of the American Association for Cancer Research 28:54-54,
3/1987.
Mendelsohn J, Peacock JS, Sunada H. Selective Phosphorylation of Tyrosine and Serine
Threonine, and Altered Intracellular Processing of the Epidermal Growth-Factor Receptor.
Proceedings of the American Association for Cancer Research 28:55-55, 3/1987.
Mendelsohn J, Masui H. Anti-Egf Receptor Monoclonal-Antibodies May Inhibit A431 TumorCell Proliferation by Blocking an Autocrine Pathway. Clinical Research 35(3):A660-A660,
4/1987.
Castagnola J, Macleod C, Sunada H, Mendelsohn J, Taetle R. Effects of Epidermal GrowthFactor (Egf) on Surface Expression and Phosphorylation of Transferrin Receptors (Tfrs) in
Malignant Epithelial-Cells. Clinical Research 35(3):A522-A522, 4/1987.
Goldenberg A, Masui H, Mendelsohn J. Egf Receptor (Egfr) Overexpression and TumorLocalization with Indium-Labeled Anti-Egfr Mab. Proceedings of the American Association for
Cancer Research 29:436-436, 3/1988.
Chen L, Mendelsohn J. The Effect of Tgf-Beta on the Proliferation and Differentiation of K562 Cells. Proceedings of the American Association for Cancer Research 29:80-80, 3/1988.
Klein SB, Mendelsohn J, Voorhees JJ, Elder JT. Tgf-Alpha Autoinduction Requires Egf
Receptor Activation. Clinical Research 38(2):A646-A646, 4/1990.
Mendelsohn J, Fan Z, Lu Y. Antibody-Mediated Receptor Dimerization and DownRegulation Enhance Inhibition of A431 Cell-Growth by Antiepidermal Growth-Factor Receptor
Monoclonal-Antibody. Clinical Research 42(2):A206-A206, 4/1994.
Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Bertness B, Mendelsohn J, Waksal L. A
study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and
cisplatin in patients with head and neck or lung carcinomas. Proc Annu Meet Am Soc Clin
Oncol 16:383a (#A1364), 1997.
Fan Z, Koff A, Lu Y, Wu X, Peng D, Chou J-L, Mendelsohn J. p27 and p21 from the Kip-Cip
family of CDK inhibitors arrest cell cycle traversal. Proc Annual Meeting Am Assoc Cancer
Res 38:497 (#A3332), 1997.
Hu G, Lui W, Mendelsohn J, Ellis L, Radinsky R, Andreeff M, Deisseroth A. Proliferation of
cervical cancer cell lines in vitro is dependent on epidermal growth factor receptor levels
which can be down regulated by decreases in the expression of the E6/E7 transforming
proteins of the integrated human papilloma virus. J Invest Med 45(3):263A, 1997.
Chou J-L, Moasser J, Kohl NE, Gibbs JB, Oliff A, Mendelsohn J, Sepp-Lorenzino L, Rosen
N. The farnesyl transferase inhibitor (FTI) induces G1 arrest in ras-transformed human
mammary epithelial cells in combination with epidermal growth factor (EGF) receptor
blockade. Proc Annual Meeting Am Assoc Cancer Res 38:63 (#A426), 1997.
Mendelsohn J. EGFR and Solid Malignancies. 44th Annual Clinical Conference: Molecular
Therapeutics for Cancer Metastasis, Houston, TX, 3/2003.
Mendelsohn J. The EGFR family as a target for cancer therapy. Biotherapy of Cancer:
From Disease to Targeted Treatment. Munich, Germany, 9/2003.
Mendelsohn J. Augmentation of chemotherapy and radiotherapy by EGF receptor inhibition.
45th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Salt
Lake City, UT, 10/2003.
Mendelsohn J. Merging medicine with science: the birth of a targeted therapy in cancer.
NHG Annual Scientific Congress, Singapore, 10/2004.
Mendelsohn J. Merging medicine with science: the birth of a targeted therapy in cancer.
NHG Annual Scientific Congress, CNIO meeting, Madrid, Spain, 11/2004.
Mendelsohn J. Targeted anti-cancer therapies: lessons learned. Oncology World Congress,
New York, NY, 11/2005.
Mendelsohn J. EGF receptor inhibitors: lessons learned. International Symposium on
Translational Research: Apoptosis and Cancer, Thirvanthapura, India, 12/2005.
Mendelsohn J. The anti-epidermal growth factor receptor monoclonal antibody
cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition
Page 23 of 38
John Mendelsohn, M.D.
63.
64.
of vascular endothelial growth factor expression. Proc Annu Meet Am Assoc Cancer Res
46:1192 (#5049), 2005.
Mendelsohn J. EGF receptor inhibitors: successes and challenges in a targeted cancer
therapy. International Congress on Anti-Cancer Treatment, Paris, France, 1/2006.
Mendelsohn J. Targeting the EGF receptor: experience and lessons. Molecular Staging of
Cancer, Heidelberg, Germany, 6/2006.
Book Chapters
1. Salzman NP, Mendelsohn J. Isolation and fractionation of metaphase chromosomes. In:
Methods in Cell Physiology. 3. Academic Press: New York, 227-292, 1968.
2. Mendelsohn J. Studies of isolated mammalian metaphase chromosomes. In: The Cell
Nucleus. II. Academic Press: New York, 123-147, 1974.
3. Snyder FF, Mendelsohn J, Seegmiller JE. Adenosine and guanosine metabolism during
phytohemagglutinin induced transformation of human lymphocytes. In: Purine Metabolism in
Mann-II: Regulation of Pathways and Enzyme Defects. Plenum Press: New York, 441-447,
1977.
4. Mendelsohn J, Dorian R, Castagnola J, Bernheim J. Is there gene amplification or other
nonduplicative DNA synthesis in human lymphocyte activation? In: Regulatory Mechanisms
in Lymphocyte Activation. Academic Press: New York, 467-469, 1977.
5. Bernheim JL, Mendelsohn J. Kinetics of DNA synthesis and cell proliferation in lymphocyte
activation [Workshop Review]. In: Regulatory Mechanisms in Lymphocyte Activation.
Academic Press: New York, 479-505, 1977.
6. Berhneim JL, Dorian R, Mendelsohn J. Pitfalls in the lymphocyte proliferation assay:
variations in proliferation kinetics and cold thymidine pools. In: Regulatory Mechanisms in
Lymphocyte Activation. Academic Press: New York, 464-466, 1977.
7. Shiftan TA, Caviles AP Jr, Mendelsohn J. Spontaneous lymphocyte proliferation in
Hodgkin's disease. In: Regulatory Mechanisms in Lymphocyte Activation. Academic Press:
New York, 677-679, 1977.
8. Mendelsohn J, Nordberg J. Adenylate cyclase in normal and leukemic human lymphocytes.
In: Cell biology and Immunology of Leukocyte Function. Academic Press: New York, 143147, 1979.
9. Bernheim JL, Mendelsohn J. Evidence for and against unusual species of DNA in
lymphocyte activation. In: Cell biology and Immunology of Leukocyte Function. Academic
Press: New York, 115-119, 1979.
10. Vyth-Dreese FA, de Vries JE, Mendelsohn J. Induction and characterization of a T-cell
growth factor (TCGF) dependent leukemic T-cell culture. In: Leukemia Markers. Academic
Press: New York, 341-344, 1981.
11. Mendelsohn J, Caviles A Jr, Castagnola J. Proliferation of normal human lymphocytes in
serum-free albumin-free medium. In: Growth of Cells in Hormonally-Defined Media. 9. Cold
Spring Harbor Laboratory: Cold Spring Harbor, 677-690, 1982.
12. Green MF, Markman M, Mendelsohn J. Supportive care. In: Cancer Chemotherapy. 4.
Elsevier: Amsterdam, 472-431, 1982.
13. Mendelsohn J, Green MR. Supportive care. In: Cancer Chemotherapy. 5. Elsevier:
Amsterdam, 479-491, 1983.
14. Mendelsohn J, Dillman RO, Royston I. Use of biological response modifiers in the
management of cancer. In: Management of Advanced Cancer. Masson Publishing, 167-193,
1983.
15. Mendelsohn J, Caviles A Jr, Castagnola J. Culture of human lymphocytes in serum-free
medium. In: Methods of Serum-Free Culture of Neuronal and Lymphoid Cells. Alan R. Liss,
Inc.: New York, 207-214, 1984.
16. Markman M, Mendelsohn J, Green MR. Supportive care. In: Cancer Chemotherapy. 6.
Elsevier: Amsterdam, 481-490, 1984.
17. MacLeod CL, Masui H, Trowbridge IS, Mendelsohn J. Monoclonal antibodies directed
towards growth-related receptors on human tumors. In: Monoclonal Antibody Therapy of
Human Cancer. Martinus Nijhoff Publishing: Boston, 57-83, 1985.
Page 24 of 38
John Mendelsohn, M.D.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Le A, Mendelsohn J, Sato GH, Sunada H, MacLeod CL. Receptor processing by
monoclonal antibodies to the EGF receptor. In: Growth and differentiation of Cells in Defined
Environments. Springer-Verlag: Heidelberg, 303-306, 1985.
Mendelsohn J. Principles of neoplasia. In: Harrison's Principles of Internal Medicine, 11th
Edition. McGraw Hill: New York, 421-454, 1987.
Mendelsohn J. Epidermal growth factor receptors as potential targets for antitumor therapy
with monoclonal antibodies. In: Growth Regulation of Cancer. Alan R. Liss, Inc.: New York,
169-173, 1988.
Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal
antibodies. In: Monoclonal Antibody Therapy. 45. Karger Publications: Basel, Switzerland,
147-160, 1988.
Mendelsohn J, Masui H, Sunada H, MacLeod C. Monoclonal antibodies against the receptor
for epidermal growth factor as potential anticancer agents. In: Cellular and Molecular Biology
of Tumors and Potential Clinical Applications. Alan R. Liss, Inc.: New York, 307-312, 1988.
Mendelsohn J. Workshop: antibodies and other biological response modifiers as
preventative, diagnostic, and therapeutic agents. In: Cellular and Molecular Biology of Tumor
and Potential Clinical Applications. Alan R. Liss, Inc.: New York, 313-315, 1988.
Mendelsohn J. Clinical perspective – cell-surface receptor proteins for growth factors as
cancer markers: epidermal growth factor receptor and HER-2/neu protein. In: Molecular
Diagnostics of Human Cancer. Cold Spring Harbor Laboratory: New York, 343-345, 1989.
Mendelsohn J. Potential clinical applications of anti-EGF receptor monoclonal antibodies. In:
Molecular Diagnostics of Human Cancer. Cold Spring Harbor Laboratory: New York, 359362, 1989.
Mendelsohn J. Antibodies to growth factors and receptors. In: Biologic Therapy of Cancer,
1st Edition. J.B. Lippincott Co.: Philadelphia, 601-612, 1991.
Mendelsohn J. Principles of neoplasia. In: Harrison's Principles of Internal Medicine, 12th
Edition. McGraw Hill: Washington, DC, 1576-1587, 1991.
Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor
monoclonal antibodies. In: Biology of and Novel Therapeutic Approaches for Epithelial
Cancers of the Aerodigestive Tract, 125-131, 1992.
Mendelsohn J. Growth-factor receptors as a target for therapy. In: Lung Cancer. Blackwell
Scientific Publications: Boston, 364-387, 1993.
Mendelsohn J. Monoclonal antibodies against receptors for cytokines as potential anticancer
agents. In: Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy.
Oxford University Press, 195-200, 1993.
Mendelsohn J, Lippman M. Principles of molecular cell biology of cancer: growth factors. In:
Cancer: Principles and Practice of Oncology, 4th Edition. J.B. Lippincott Co.: Philadelphia,
114-133, 1993.
Mendelsohn J. Anti-EGF receptor monoclonal antibodies as potential anti-cancer therapy.
In: Cancer Treatment: An Update. Springer-Verlag: Heidelberg, 17-18, 1994.
Mendelsohn J. Principles of neoplasia. In: Harrison's Principles of Internal Medicine, 13th
Edition. McGraw Hill, Inc.: Washington, DC, 1814-1826, 1994.
Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer
therapy. In: Pharmacology and Therapeutics. 64. Pergamon Press, Elsevier Science Ltd.:
London, 127-154, 1994.
Mendelsohn J, Baselga J. Antibodies to growth factors and receptors. In: Biologic Therapy
of Cancer, 2nd Edition. J.B. Lippincott Co.: Philadelphia, 607-623, 1995.
Mendelsohn J, Gabrilove J. Growth factors in malignancy. In: The Molecular Basis of
Cancer. W.B. Saunders Co.: Philadelphia, 432-459, 1995.
Baselga J, Mendelsohn J. Interaction of biologic agents with chemotherapy. In: Biologic
Therapy of Cancer, 2nd Edition. J.B. Lippincott Co.: Philadelphia, 863-875, 1995.
Mendelsohn J, Fan Z, Baselga J. Combination therapy with cisplatinum and EGF receptor
blockade. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy.
2. Plenum Press: New York, 115-163, 1996.
Page 25 of 38
John Mendelsohn, M.D.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
Mendelsohn J, Baselga J, Wu X, Peng D, Brown C, Chou J-L, Fan Z. EGF receptor
inhibition by antibody as anticancer therapy. In: EGF Receptor in Tumor Growth and
Progression. Springer-Verlag: Heidelberg, 233-251, 1997.
Grant SC, Lynch SA, Mendelsohn J. Growth factors in lung cancer: current status and
implications for therapy. In: Growth Factors and Cytokines in Health and Disease. Volume
3B: Systems. Jai Press: Greenwich, CT, 355-380, 1997.
Mendelsohn J. Target therapy: the EGF receptor. In: Progress in Cancer Therapy. II.
Blackwell Science: Boston, 1997.
Perez-Solar R, Mendelsohn J. Growth-factor receptors as a target for therapy. In: Lung
Cancer, 2nd Edition. Blackwell Science, Inc.: Malden, MA, 309-341, 1998.
Grant S, Early E, Mendelsohn J. Monoclonal Antibodies in the Management of Lung Cancer.
In: Monoclonal Antibody-Based Therapy of Cancer. Dekker: New York, NY, 365, 1998.
Fan Z, Mendelsohn J. Breast cancer therapy using monoclonal antibodies against epidermal
growth factor receptor and HER-2. In: Breast Cancer: Molecular Genetics, Pathogenesis and
Therapeutics. Humana Press: Totowa, NJ, 419-436, 1999.
Baselga J, Mendelsohn J. Monoclonal antibodies directed against growth factor receptors.
In: Biologic Therapy of Cancer, 3rd Edition. Lippincott, Williams & Wilkins: Philadelphia, 475489, 2000.
Mendelsohn J, Baird A, Fan Z, Markowitz S. Growth factors and their receptors in epithelial
malignancies. In: The Molecular Basis of Cancer, 2nd Edition. W.B. Saunders Company:
Philadelphia, 137-161, 2001.
Herbst R, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. In: Signal
Transduction in Cancer. Ed(s) DA Frank. Kluwer Academic Publishers: The Netherlands, 1972, 2003.
Onn A, Mendelsohn J, Herbst RS. Targeting the epidermal growth factor receptor in the
clinic. In: Progress in Oncology. Volume IV. Jones and Bartlett Publishers: Boston Toronto
London Singapore, 73-100, 2004.
Mendelsohn J. Development of a targeted treatment for cancer: the example of C225
(Cetuximab). In: Molecular Targeting in Oncology. Humana Press, 2008.
Mendelsohn J, Powis G. From bench to bedside with targeted therapies. In: The Molecular
Basis of Cancer, 3rd Edition. W.B. Saunders Co.: Philadelphia. In Press.
Books (edited and written)
1. nknown. Ed(s) J Mendelsohn, Guest Editor. New Concepts in Oncology. Harrison's
Principles of Internal Medicine. Update VII. McGraw Hill: New York, 1986.
2. nknown. Ed(s) J Mendelsohn, P Howley, L Liotta, M Israel. The Molecular Basis of Cancer.
W.B. Saunders Co.: Philadelphia, 1995.
3. nknown. Ed(s) J Mendelsohn, P Howley, L Liotta, M Israel. The Molecular Basis of Cancer,
2nd Edition. W.B. Saunders Co.: Philadelphia, 2001.
4. nknown. Ed(s) J Mendelsohn, P Howley, M Israel, J Gray, CB Thompson. The Molecular
Basis of Cancer, 3rd Edition. W.B. Saunders Co.: Philadelphia, 2008.
5. Mendelsohn J, Powis G. The Molecular Basis of Cancer. In: From Bench to Bedside with
Targeted Therapies, 4th Edition. W.B. Saunders Co.: Philadelphia. In Press.
Letters to the Editor
N/A
Manuals, Teaching Aids, Other Teaching Publications
1. Mendelsohn J. Epidermal growth factor receptor blockade as anticancer therapy, 39-41,
2001.
Other Publications
1. Special Interview. Mendelsohn J.  Innovative care, when standard care doesn't work
and in all situations the highest quality care.  Cancer Centers Around the World 1(2):35, 1996.
EDITORIAL AND REVIEW ACTIVITIES
Editor/Service on Editorial Board(s)
Page 26 of 38
John Mendelsohn, M.D.
Editorial Board, Journal of Immunology, 1979-1983
Editorial Board, Blood, 1983-1987
Editorial Board, Journal of Clinical Oncology, 1985-1989
Associate Editor, Cancer Research, 1986-1995
Editorial Board, Growth Factors, 1988-2008
Editorial Board, Journal of Biological Response Modifiers, 1990-1998
Founding Editor-in-Chief, Clinical Cancer Research, 1994-2004
Editorial Board, Expert Review of Anticancer Therapy, 2000
Editorial Board, Molecular Oncology, 2000
Editorial Board, Molecular Oncology, 2006
Member of Editorial Review Board
N/A
Journal Reviewer
N/A
Other Editorial and Review Activities
N/A
TEACHING
Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center
Formal Teaching
Courses Taught
Lecturer, Medical Oncology Fellows Weekly Lecture Series
1997
Professor, Human Cancer Immunotherapy, UT Graduate School of Biomedical Sciences,
Course Number: GS060133
Spring, 1999
Professor, Immunotherapy of Cancer with Monoclonal Ab, UT Graduate School of
Biomedical Sciences, Course Number: GS040063
Spring, 2001
11/2002
Fall, 2005
Fall, 2006
Fall, 11/2008
Professor, Inhibition of EGF Receptors with a Monoclonal Antibody as Anticancer
Therapy: From the Bench to the Bedside, UT Graduate School of Biomedical Sciences
Spring, 2001
Professor, Receptor Blockade as Anti-Cancer Therapy, UT Graduate School of
Biomedical Sciences
4/2002
Professor, Cancer Biology !, Immunotherapy of Cancer with Monoclonal Ab, U.T.
Graduate School of Biomedical Sciences, Course Number: GS040063
Fall, 11/2002
Speaker, EGF Receptor Blockade
4/2003
Professor, Anti-EGFR Monoclonal Antibody as a Cancer Therapy, UT Graduate School of
Biomedical Sciences
Spring, 2003
Page 27 of 38
John Mendelsohn, M.D.
Professor, Targeting the EGF Receptor for Cancer Therapy, UT Graduate School of
Biomedical Sciences
Spring, 2003
Professor, The EGF Receptor as a Target for Cancer Therapy, UT Graduate School of
Biomedical Sciences
Spring, 2004
Fall, 2004
Lecturer, Targeting the EGF Receptor: Accomplishments and Challenges over 25 Years
Spring, 3/2006
Fall, 9/2006
Professor, Targeting the EGF Receptor: Accomplishments and Challenges over 25 Years,
UT Graduate School of Biomedical Sciences
Spring, 2006
Professor, EGFR and its Inhibition, UT Graduate School of Biomedical Sciences
Spring, 2007
Professor, Targeting EGF Receptors: The Journey Continues, UT Graduate School of
Biomedical Sciences
Fall, 2007
Instructor, GME - Core Curriculum Lecture Series - Targeting Therapy for Cancer:
Accelerating the Pace
3/2008
Instructor, GSBS Mechanisms in Cancer Therapeutics - EGFR and its Inhibition
3/2008
Professor, Targeting the EGF Receptor for Personalized Cancer Therapy, UT Graduate
School of Biomedical Sciences
4/2009
Professor, Targeting the EGF Receptor for Personalized Cancer Therapy
5/2009
Lecturer, Targeting the EFF Receptor: GSBS Mechanisms in Cancer Therapeutics
Course
11/2012
Training Programs
N/A
Other Formal Teaching
Speaker, Grand Rounds, Receptor Blockade and Chemotherapy: A New Combination
Treatment
1/1995
Speaker, Grand Rounds, Blockade of EGF Receptor as Anti-Cancer Therapy
9/1996
Speaker, Grand Rounds, Advances in Oncology
8/1997
Speaker, Grand Rounds, Receptor Blockade by Monoclonal Antibody 225
1998
Speaker, Grand Rounds, Receptor Targeted Therapy
2/2001
Speaker, Commercialization of Discoveries in Academia
12/2001
Speaker, Targeting EGF Receptors: The Journey Continues
Page 28 of 38
John Mendelsohn, M.D.
1/2008
Lecturer, Research Symposium -- Anti-EGF Receptor Therapy: Improving Our Aim at the
Target
9/2011
Lecturer, Grand Rounds: Targeted Cancer Therapy - A Perspective Over 30 Years
11/2011
Lecturer, Grand Rounds: Targeted Cancer Therapy Becomes Personalized
1/2012
Lecturer, Grand Rounds: Personalized Cancer Therapy
5/2012
Lecturer, Karolinska Institutet Collaborative Workshop, Course Number: Karolinska
Institute
6/2012
Lecturer, Karolinska Institutet Collaborative Workshop
9/2012
Lecturer, Leadership America / Leadership Texas
9/2012
Lecturer, Japan Health Foundation: Personalized Cancer Therapy
10/2012
Lecturer, Targeting the EGF Receptor - Center for Clinical and Translational Sciences
1/2013
Lecturer, Targeting the EGF Receptor - Core Curriculum Lecture Series
1/2013
Supervisory Teaching
Committees
Advisory Committees
N/A
Supervisory Committees
N/A
Examining Committees
N/A
Direct Supervision
Undergraduate and Allied Health Students
N/A
Medical Students
N/A
Graduate Students
N/A
Postdoctoral Research Fellows
N/A
Clinical Residents and Fellows
N/A
Other Supervisory Teaching
N/A
Teaching Outside Current Institution
Formal Teaching
Courses Taught
Page 29 of 38
John Mendelsohn, M.D.
Professor, Cancer Biology, UT Graduate School of Biomedical Sciences, Course Number:
GS04 0063
11/2001
Training Programs
N/A
Other Formal Teaching
N/A
Supervisory Teaching
Committees
Advisory Committees
N/A
Supervisory Committees
N/A
Examining Committees
N/A
Direct Supervision
Undergraduate and Allied Health Students
N/A
Medical Students
N/A
Graduate Students
N/A
Postdoctoral Research Fellows
N/A
Clinical Residents and Fellows
N/A
Other Supervisory Teaching
N/A
CONFERENCES AND SYMPOSIA
Organization of Conferences/Symposia (Include chairing session)
National Institute of Health, Internal Review of Antibody Therapy, Bethesda, MD, Keynote
Speaker, 2/1994
AA0, ASCI, AFCR, Clinical Research Meeting, Baltimore, MD, Co-Chair, 4/1994
American Association for Cancer Research, Annual Meeting, Toronto, Canada, Chair, 3/1995
American Society of Hematology, Neoplasia Symposium, Nashville, TN, Chair, 12/1995
NCI-EORTC, New Drugs in Cancer Therapy, Amsterdam, Netherlands, Chair, 3/1996
American Association for Cancer Research, Targeting Growth Factor Receptors for Therapy,
Washington, DC, Chair, 4/1996
Semi-Annual Meeting of the Radiation Therapy Oncology Group, Receptor Blockade as AntiCancer Therapy, Houston, TX, Keynote Speaker, 2/1997
9th International Congress on Anti-Cancer Treatment, Scientific Committee and International
Advisory Board, Member, 1999
American Association for Cancer Research, 90th Annual Metting, Philadelphia, PA, Chair, 4/1999
International Conference on Basic and Clinical Aspects of Cell Cycle Control, Blockade of
Receptors for Growth Factors as Anti-Cancer Therapy, Siena, Italy, Keynote Speaker, 5/2000
Page 30 of 38
John Mendelsohn, M.D.
American Association for the Advancement of Science, Electorate Nominating Committee for the
Section on Medical Sciences, Member, 2001
American Society of Clinical Oncology, Scientific Symposium - Targeting Receptors in the EGF
Receptor Family for Therapy, San Francisco, CA, Chair, 5/2001
American Association for Cancer Research, 93rd Annual Meeting - Symposium: The EGF
Receptor (HER) Family as a Target for Therapy, San Francisco, CA, Chair, 4/2002
American Society of Clinical Oncology, 38th Annual Meeting - Symposium: Principles of
Molecular Oncology: From Clinic to Bench, Orlando, FL, Chair, 5/2002
1st International Symposium on Signal Transduction Modulators in Cancer Therapy, Co-chair,
Organizing Committee, Targerting the EGF Receptor in Cancer Therapy, Amsterdam,
Netherlands, Keynote Speaker, 9/2002
First International Symposium on Anti-Receptor Signaling Strategies in Human Neoplasia, Antitumor Mechanisms of EGF Receptor Inhibition, Chicago, IL, Keynote Speaker, 9/2002
American Society of Clinical Oncology, 39th Annual Meeting - Symposium: Principles of
Molecular Oncology: From Clinic to the Bench, Chicago, IL, Chair, 5/2003
American Association of Cancer Research, Annual Meeting - Mini Symposium: Molecular
Correlates of Response and Survival, Anaheim, CA, Co-Chair, 4/2005
The Banbury Center - Cold Spring Harbor Laboratory, EGF Receptors as Targets: Progress and
Lessons Learned, Cold Spring Harbor, NY, Keynote Speaker, 11/2005
The University of Texas MD Anderson Cancer Center, Pathololgy of the 21st Integrating
Diagnostic and Molecular Pathology, Houston, TX, Keynote Speaker, 5/2006
Institute of Medicine, National Cancer Policy Forum, Improving the Quality of Cancer Clinical
Trials Workshop, Bethesda, MD, Member, 2007
The University of Texas MD Anderson Cancer Center, Pathology Conference, Clinical Practice in
the Era of Molecular Medicine, Houston, TX, Keynote Speaker, 5/2007
The University of Texas MD Anderson Cancer Center, Pathology of the 21st Century,
Individualized Therapy Approaches, Houston, TX, Keynote Speaker, 5/2008
2008 Symposium of Multinational Association of Supportive Care in Cancer, History and Promise
of Targeted Therapy, Houston, TX, Keynote Speaker, 6/2008
American Physician Scientists Association - Texas Region, American Physician Scientists,
Houston, TX, Keynote Speaker, 11/2008
Internal Joint Retreat - Center for Biological Pathways, Targeting the EGF Receptor: Past,
Present, Future, Houston, TX, Keynote Speaker, 1/2009
5th Annual Moores Cancer Center Translational Oncology Symposium, Targeted Therapy for
Cancer: Lessons from Cetuximab, San Diego, CA, Keynote Speaker, 2/2009
2009 Nanotech Conference, Nano Science and Technology Institute, Houston, TX, Keynote
Speaker, 5/2009
Presentations at National or International Conferences
Invited
Immunotherapy with Antireceptor Monoclonal Antibodies, American Association for Cancer
Research, Interlaken, Switzerland, 3/5/1994
Monoclonal Antibodies Directed Against Growth Factor Receptors Enhance the Efficacy of
Chemotherapeutic Agents, 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy,
Amsterdam, Netherlands, 3/17/1994
EGF Receptor Blockade with Monoclonal Antibodies, 7th World Conference on Lung Cancer Biology Mini-Symposium on Growth Factors, Colorado Springs, CO, 6/30/1994
Anti-EGF Receptor Antibodies, Workshop on Breast Cancer, Capri, Italy, 10/2/1994
Page 31 of 38
John Mendelsohn, M.D.
Growth Factors and Promotion of Cancer: Therapeutic Implications, Fifth International
Congress on Anti-Cancer Chemotherapy, Paris, France, 2/2/1995
Interaction of Growth Factors and Platinum, 7th International Symposium on Platinum and
Other Metal Coordinating Compounds in Cancer Chemotherapy, Amsterdam, Netherlands,
3/6/1995
Blockade of Growth Factor Receptors as Anticancer Therapy, Clinical Research Meetings of
AFCR/ASCI/AAP, San Diego, CA, 5/6/1995
Growth Factors: A New Target for Therapy in Breast Cancer, American Society of Clinical
Oncology, Los Angeles, CA, 5/20/1995
Antireceptor Antibodies as Anticancer Therapy: Preclinical and Clinical Studies, Cancer
Research Institute Symposium, New York, NY, 10/17/1995
Receptor Inhibition by Antibody as Anticancer Therapy, 7th International Congress on AntiCancer Treatments Bourgine Award Recipient, Paris, France, 2/6/1997
Exploiting EGFR as a Therapy Target, 5th Annual Genitourinary Oncology Conference Advances in the Biology and Therapy of Prostate Cancer, The University of Texas
MD Anderson Cancer Center, Houston, TX, 2/20/1997
Blockade of Signal Transduction as Anticancer Therapy, 29th International Symposium of The
Princess Takamatsu Cancer Research Fund - Molecular Basis for Invasion and Metastasis,
Tokyo, Japan, 11/17/1998
Cancer Centers as Translational Research Engines, 90th Annual Meeting - American
Association of Cancer Research - Special Session: The Future of Cancer Research Centers,
Philadelphia, PA, 4/12/1999
Receptor Tyrosine Kinase Targets, AACR/NCI/EORTC International Conference on Molecular
Targets and Cancer Therapeutics - Plenary Session: Biology and Target Selection,
Washington, DC, 11/16/1999
Receptor Blockade as Anticancer Therapy, Killing Cancer Cells Symposium, The Netherlands
Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, 11/19/1999
What are the new areas of innovation in research, World Summit Against Cancer for the New
Millennium Under the Patronage of U.N.E.S.C.O., Paris, France, 2/3/2000
Blockade of Receptors for Growth Factors as Anti-Cancer Therapy, 5th International
Conference on Head and Neck Cancer, San Francisco, CA, 7/31/2000
Inhibition of EGF Receptors as Anticancer Therapy, Royal College of Physicians - Society for
Endocrinology, London, United Kingdom, 11/21/2000
EGFR: A Target for Anti-Tumor Agents, 12th International Cancer Congress, Paris, France,
2/5/2002
Targeted Therapy of Solid Tumors: An Idea Whose Time Has Come, Scripps Cancer Center
Annual Conference: Clinical Hematology and Oncology 2002, La Jolla, CA, 2/18/2002
Targeting the EGF Receptor for Cancer Therapy, 38th Annual ASCO Meeting, Orlando, FL,
5/18/2002
Targeting Drugs Against Cancer, 17th Meeting of the European Association for Cancer
Research, Granada, Spain, 6/11/2002
Inhibition of Growth Factor Signaling as Anticancer Therapy, II European Spring Oncology
Conference (ESOC), Malaga, Spain, 6/12/2002
Targeting the EGF Receptor in Cancer Therapy, First International Symposium on Signal
Transduction Modulators in Cancer Therapy, Amsterdam, Netherlands, 9/23/2002
Targeted Cancer Therapy, Medicine in 21st Century: First Sino-US Symposium, Houston, TX,
12/11/2002
Page 32 of 38
John Mendelsohn, M.D.
The EGF Receptor as a Target for Cancer Therapy, 5th Pan Arab Cancer Congress, Kuwait
City, 4/5/2004
Merging Medicine and Science: The Birth of a Targeted Therapy in Cancer, National
Healthcare Group Annual Scientific Congress 2004, Singapore, Singapore, 10/9/2004
Development of EGF Receptor Antibody in Human Cancer Treatment, Laurea ad Honereum in
Medicine and Surgery, Second University of Naples, Naples, Italy, 6/7/2005
EGF Receptors Targets: Progress and Lessons Learned, Oncology World Congress, New
York, NY, 11/19/2005
The EGF Receptor as a Target for Cancer Therapy, Society of Surgical Oncology, The John
Wayne Clinical Research Lecture, Washington, DC, 3/17/2007
Targeting EGF Receptors: The Journey Continues, Mechanisms of Tumor Control
Symposium, A. C. Camargo, Sao Paulo, Brazil, 11/12/2007
Inhibition of the EGF Receptor Family as Cancer Therapy, American Italian Cancer
Foundation Symposium, New York, NY, 11/20/2007
Targeting Therapy for Cancer: Accelerating the Pace, 2008 AACR Annual Meeting - Dorothy
P. Landon Lecture, San Diego, CA, 4/14/2008
10th International Medical Education Workshop on Molecular Targeted Therapy of Cancer,
Prague, Czech Republic, 6/12/2009
Mendelsohn, John. MD Anderson Cancer Center Institute for Personalized Cancer Therapy,
American Cancer Society, ACR, Atlanta, GA, 11/2011
Mendelsohn, John. Targeted Cancer Therapy - A Perspective Over 30 Years, International
Symposium on Translational Cancer Research Cancer Prevention, Udaipur, Rajasthan State,
India, 12/17/2011
Personalized Cancer Therapy, European Association for Cancer Research, EACR-22,
Barcelona, Spain, 7/7/2012
Other, Including Scientific Exhibitions
EGF Receptor - Targeted Therapy: New Challenges, 14th EORTC-NCI_AACR Symposium on
Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, 11/19/2002
Targeting the EGF Receptor: The Journey Continues, Symposium Honoring Dr. Zvi Fuks,
Memorial Sloan-Kettering Cancer Center, New York, NY, 5/21/2007
Mendelsohn, John. Customized Cancer Treatment: A Systems Biology Approach to Drug
Selection, American Society of Clinical Oncology, ASCO, Chicago, IL, 6/3/2011
Customized Cancer Medicine: Are We Ready?, Worldwide Innovative Network (WIN), Paris,
France, 7/6/2011
Mendelsohn, John. Personalized Cancer Therapy, American Society of Clinical Oncology,
ASCO, Chicago, IL, 6/4/2012
Mendelsohn, John. Personalized Cancer Therapy, American Association for Cancer
Research, PMC/AACR, Washington, DC, 6/12/2012
WIN Symposium: Win with Personalized Cancer Therapy, Worldwide Innovative Network
(WIN), Paris, France, 6/28/2012
Seminar Invitations from Other Institutions
Receptor Blockade and Chemotherapy: A New Cancer Treatment, Parke Davis Pharmaceutical
Company, Detroit, MI, 12/7/1994
EGF Receptor Blockade as Cancer Therapy, Experimental Oncology, Ernst Schering Research
Foundation, Berlin, Germany, 1/31/1995
Invited Speaker: Panel to Assess NIH Investment in Research on Gene Therapy, National
Institutes of Health, Bethesda, MD, 7/13/1995
Page 33 of 38
John Mendelsohn, M.D.
Growth Factor Receptors as a Therapeutic Target, Distinguished Lecture Series, The Cancer
Institute of New Jersey, New Brunswick, NJ, 9/20/1995
Growth Factor Receptors as a Therapeutic Target, Current Concepts in Medical Oncology,
Memorial Sloan-Kettering Cancer Center, New York, NY, 10/25/1995
Antibodies to Growth Factor Receptors, Winter Scientific Meeting and Basic Science Forum,
British Association of Surgical Oncology, London, Unknown, United Kingdom, 11/23/1995
Cancer as a Disease of the Cell Cycle: Clinical Applications, The Science Writers' Seminar,
Memorial Sloan-Kettering Cancer Center, New York, NY, 1/25/1996
EGF Receptor in Tumor Growth and Progression, Ernst Schering Research Foundation, Berlin,
Germany, 3/27/1996
Receptor Blockade as Anticancer Therapy, Seminars in Clinical and Molecular Oncology,
National Cancer Institute/Division of Clinical Sciences, Washington, DC, 3/3/1998
Real Progress in Targeted Cancer therapy, Bristol-Myers Squibb Oncology Academy, New
Orleans, LA, 5/19/2000
EGF Receptor Blockage - A New Anticancer Therapy, Baylor College of Medicine - Tumor Board,
Houston, TX, 4/12/2002
The EGF Receptor as a Target for Cancer Therapy, University of Cairo, Cairo, Egypt, 4/12/2004
Translation of Science into Clinical Practice: Lessons from Research on EGF Receptor Inhibitors,
Vanderbilt-Ingram Cancer Center, Nashville, TN, 3/23/2005
Genomic Cancer Medicine: The EGF Receptor as an Example, Baker Institute for Public Policy,
Rice University, Houston, TX, 2/5/2013
Lectureships and Visiting Professorships
Visiting Professor, Netherlands Cancer Institute, Amsterdam, Netherlands, 1978
EGF Receptors as a Target for Therapy in Human Malignancy, Grand Rounds, Yale University
School of Medicine, New Haven, CT, 1/27/1994
Anti-EGF Receptor Monoclonal Antibodies as Anti-Cancer Agents, Vanderbilt University Cancer
Center, Nashville, TN, 5/11/1994
Receptor Blockade Monoclonal Antibodies as Anti-Cancer Agents, Grand Rounds, Mount Sinai
Hospital, New York, NY, 12/16/1994
Growth Factors and Cellular Receptors, Core Curriculum in Oncology for Medical Oncology
Fellows, Memorial Sloan-Kettering Cancer Center, New York, NY, 3/9/1995
Blockade of Growth Factor Receptors as Anticancer Therapy, Rosewell Park Cancer Institute,
Buffalo, NY, 4/21/1995
Growth Factor Receptors: A New Target for Cancer Therapy, Tri-Institutional MD-PhD Program,
Cornell University Medical College, New York, NY, 5/9/1995
Targeting Growth Factors and Cytokines, Molecular Pharmacology of Cancer Course, Memorial
Sloan-Kettering Cancer Center, New York, NY, 5/10/1995
Receptors as Cancer Treatment Targets, Thoracic Service Grand Rounds, Memorial SloanKettering Cancer Center, New York, NY, 2/2/1996
Blockade of EGF Receptors as Anti-Cancer Therapy, Medical School Lecture Series, The
University of Texas Health Science Center Medical School, Houston, TX, 12/11/1996
Grand Rounds - Department of Surgery, Baylor College of Medicine, Houston, TX, 5/31/1997
Quality Healthcare in the Changing World, Barbara Hurwitz Lecture Series - Managing in a
Changing World, University of St. Thomas, Houston, TX, 4/23/1998
Page 34 of 38
John Mendelsohn, M.D.
Blockade of Receptors for Growth Factors as Anti-Cancer Therapy, 4th Joseph H. Burchenal
AACR Clinical Research Award Lecture, 90th Annual Meeting - American Association for Cancer
Research, Philadelphia, PA, 4/12/1999
New Targets for Cancer Therapy, 10th Anniversary Barrett Cancer Center Distinguished Lecture
Series, University of Cincinnati Medical Center, Cincinnati, OH, 5/28/1999
Targeted Cancer Therapy, The Jeremiah Metzger Lecture, 112th Meeting of the American Clinical
Climatological Association, San Diego, CA, 10/26/1999
Blockade of EGF Receptors for Anti-Cancer Therapy, The Willet F. Whitmore, Jr. Lectureship,
Society of Urologic Oncology, Atlanta, GA, 4/29/2000
Anti-Receptor Antibodies as Anticancer Therapy, Grand Rounds, Baylor College of Medicine,
Houston, TX, 9/28/2000
Inhibition of EGF Receptors as Anticancer Therapy, Keystone Symposium - Cancer Intervention,
Keystone Symposium, Durango, CO, 3/1/2001
Growth Factor Receptor Blockade as Anticancer Therapy, Alan C. Sartorelli Lecture, Yale
University, New Haven, CT, 5/31/2001
Anti-Receptor Therapy, Woodward Lecture Medical Grand Rounds, Memorial Sloan-Kettering
Cancer Center, New York, NY, 6/1/2001
Medical Grand Rounds, New York University School of Medicine, New York, NY, 11/14/2001
Targeting the EGF Receptor for Cancer Therapy, Simon M. Shubitz Award Lecture, The
University of Chicago Cancer Research Foundation, Chicago, IL, 5/13/2002
The EGF Receptor Tyrosine Kinase as a Target for Cancer Therapy, Distinguished Lecture
Series, Cancer Institute of of New Jersey, NJ, 11/17/2004
The EGF Receptor Tyrosine Kinase as a Target for Cancer Therapy, McPeak Lectureship,
Memorial Sloan-Kettering Cancer Center, New York, NY, 11/18/2004
The Dream of Personalized Cancer Medicine: 25 Years Investigating a Targeted Therapy, The
Dan David Prize Lecture, Tel Aviv University, Paris, France, 3/7/2007
Targeting EGF Receptors: The Future is Now, Janeway Lecture, American Radium Society,
Laguna Nigel, CA, 5/6/2008
Targeted Cancer Therapy, Medicine Grand Rounds, The Methodist Hospital System, Houston,
TX, 6/10/2008
Targeting Therapy for Cancer: Accelerating the Pace, Comprehensive Cancer Center Grand
Rounds, Ohio State University, Columbus, OH, 6/20/2008
Targeted Therapy for Cancer: Lessons from Cetuximab, Internal Medicine Grand Rounds, UT
Southwestern Medical Center at Houston, Dallas, TX, 9/26/2008
Targeting Therapy for Cancer: Accelerating the Pace, 2009 Kirk A. Landon Translational Cancer
Research Lecture, American Association for Cancer Research, Miamy, FL, 1/23/2009
Targeting the EGF Receptor for Personalized Cancer Therapy, 2009 Lila Gruber Memorial
Cancer Research Award and Lectureship, American Association of Dermatology, San Francisco,
3/8/2009
MD Anderson Cancer Center Institute for Personalized Cancer Therapy, Personalized Medicine
Conference, The Broad Institute, Cambridge, MA, 11/9/2011
Targeted Cancer Therapy - A Perspective Over 30 Years, David H. Koch Institute for Integrative
Cancer Medicine at MIT, Cambridge, MA, 2/14/2012
Targeting Growth Factors and Cytokines, Molecular Pharmacology of Cancer Center, Memorial
Sloan-Kettering Cancer Center, New York, NY
Other Presentations at State and Local Conferences
Page 35 of 38
John Mendelsohn, M.D.
Receptors for Growth Factors, Freireich Symposium - Foundations of Clinical Cancer Research,
The University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/15/1997
Advances in Cancer Research: The Science of Hope, "Living Fully with Cancer," Anderson
Network Conference, The University of Texas M. D. Anderson Cancer Center, Houston, TX,
9/1/1997
Receptor Inhibition by Antibody as Anticancer Therapy, M. D. Anderson Cancer Center 50th
Annual Symposium on Fundamental Cancer Research, The University of Texas M. D. Anderson
Cancer Center, Houston, TX, 10/28/1997
Targeting Growth Factor Receptors, M. D. Anderson's 41'st Annual Clinical Conference - New
Frontiers in Research and Treatment of Aerodigestive Tract Cancers, The University of Texas M.
D. Anderson Cancer Center, Houston, TX, 4/21/1998
C225: A New Approach to Cancer Therapy, The University of Texas M. D. Anderson Cancer
Center's Community Clinical Oncology Program, The University of Texas M. D. Anderson Cancer
Center, Houston, TX, 9/15/2000
Anti-EGF Receptor Cancer Therapy, Texas Academy of Internal Medicine, Houston, TX,
11/4/2000
Making Cancer History, Symposium - Neurosurgical Oncology: The Decade Ahead, The
University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/26/2001
Breakthroughs in Cancer Research, Day of Science, The University of Texas M. D. Anderson
Cancer Center, Houston, TX, 5/3/2001
Living Fully with Cancer, Anderson Network Circle of Life, The University of Texas M. D.
Anderson Cancer Center, Houston, TX, 9/8/2001
Texas Medical Center Fellows Site Visit, Panel Session, The University of Texas M. D. Anderson
Cancer Center, Houston, TX, 10/1/2001
EGFR and Solid Malignancies, 44th Annual Clinical Conference: Molecular Therapeutics for
Cancer Metastasis, The University of Texas M. D. Anderson Cancer Center, Houston, TX,
3/20/2003
Making Cancer History - The Next Decade of Cancer Research, Young President's Organization,
Houston, TX, 3/30/2005
The M. D. Anderson Story, Roles of Physicians and Scientists in Business World, Collaborative
live-cast course at Harvard and The University of Texas M. D. Anderson Cancer Center, The
University of Texas M. D. Anderson Cancer Center, Houston, TX, 4/21/2005
Future of Research at M. D. Anderson Cancer Center, Baylor College of Medicine and The
University of Texas M. D. Anderson Cancer Center, Baylor College of Medicine, Houston, TX,
6/30/2006
Targeting EGF Receptors: A Journey that Continues, The University of Texas M. D. Anderson
Cancer Center, Houston, TX, 3/17/2007
Plans for Patient Care and Research, M. D. Anderson Medical Physics Alumni, The University of
Texas M. D. Anderson Cancer Center, Houston, TX, 7/29/2008
Mendelsohn, John. Progress in the War on Cancer, TAMEST, TAMEST, The Academy of
Medicine, Engineering and Science of Texas, Austin, TX, 1/6/2011
Mendelsohn, John. Institute for Personalized Cancer Therapy, Experimental Radiation Oncology,
The University of Texas MD Anderson Cancer Center, Houston, TX, 3/28/2012
Mendelsohn, John. Personalized Cancer Therapy, Division of Surgery Grand Rounds, The
University of Texas MD Anderson Cancer Center, Houston, TX, 5/23/2012
Mendelsohn, John. Personalized Cancer Therapy, T.T. Chao Symposium, Chemical Heritage
Foundation, Houston, TX, 10/24/2012
Page 36 of 38
John Mendelsohn, M.D.
Mendelsohn, John. The University of Texas MD Anderson Cancer Center, Center for Houston's
Future, Center for Houston's Future, Houston, TX, 2/22/2013
PROFESSIONAL MEMBERSHIPS/ACTIVITIES
Professional Society Activities, with Offices Held
National and International
American Medical Association
Member, 1967-present
American Association of Immunologists
Member, 1973-present
American Association for Cancer Research
Member, 1977-present
Chairman, Nominating Committee, 1987-1989
Public Affairs Committee, 1988-1989
Board of Directors, 1990-1993
Member (elected), Board of Directors, 1990-1993
Chairman, Publications Committee, 1991-1994
Finance Committee, 1991-1994
Founding Editor-in-Chief, Clinical Cancer Research, 1994-2004
Member, Nominating Committee for the Clinical Research and Experimental Therapeutics
Awards, 2004-2005
Co-Chairperson, Selection Committee, Clinical Research Awards Committee, 2004
Member, The Leadership Council of the President's Circle, 2006-present
Member, The Leadership Council of the President's Circle, AACR Foundation for the
Prevention and Cure of Cancer, 2006-present
American Society of Clinical Oncology
Member, 1978-present
Chairman, Program Committee, 1987
Chair, Molecular Oncology Committee, 2000-2001
Member, Roster of Cancer Experts, 2005-present
American Cancer Society
Member, Board of Directors, 1981-1985
American Society for Clinical Investigation
Member, 1985-present
Harvey Society
Member, 1985-present
American Society of Hematology
Member, 1996-present
Chairman, Scientific Subcommittee on Neoplasia, 1997
Association of American Cancer Institutes
Member, Board of Directors, 2006-present
American Association of Cancer Research
Chair, Selection Committee for the Clinical Research and Experimental, 2007-2008
National Cancer Policy Forum, Washington, DC
Chair, 2012-present
American Clinical and Climatological Association
American College of Physicians
Association of American Physicians
Leukemia Society of America, Grant Review Subcommittee
Page 37 of 38
John Mendelsohn, M.D.
Local/State
New York Academy of Medicine
Member, 1985-present
The Practitioners Society of New York
Member, 1985-present
Harris County Medical Society, TX
Member, 1996-present
Texas Medical Association, TX
Member, 1996-present
Consultant, 2004-present
UNIQUE ACTIVITIES
1. Field of Current Research: The role of growth factors and their receptors in regulating tumor cell
growth.
2. Member, The Century Association, 1987
3. Member, Rotary Club of Houston, Houston, TX, 1996
4. Vice Chairman, BioHouston, 2002
5. Member, Philosophical Society of Texas, 2008
6. Member, Junior Achievement of Southeast Texas, Inc., 2009
7. Chair Elect, Houston Grand Opera, 2013 - 2015
8. Board Member, Center for Houston's Future
DATE OF LAST CV UPDATE
3/19/2013
Page 38 of 38